<?xml version="1.0" encoding="UTF-8"?>
<rr:ResultsReport xmlns:rr="http://integration.foundationmedicine.com/reporting" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd">
  <rr:CustomerInformation>
    <rr:ReferenceID>01-2023-00029852</rr:ReferenceID>
    <rr:CSN />
    <rr:TRF>ORD-1640271-01</rr:TRF>
    <rr:MRN>40079638</rr:MRN>
    <rr:PhysicianId>109266</rr:PhysicianId>
    <rr:NPI />
  </rr:CustomerInformation>
  <rr:ResultsPayload>
    <FinalReport xmlns:xsd="http://www.w3.org/2001/XMLSchema" StagingId="1327648" clinicalId="1328995" xsi:noNamespaceSchemaLocation="http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd">
      <Application>
        <ApplicationSettings>
          <ApplicationSetting>
            <Name>Statement</Name>
            <Value />
          </ApplicationSetting>
        </ApplicationSettings>
      </Application>
      <DemographicCorrectionDate />
      <ReportId>ORD-1640271-01</ReportId>
      <SampleName>US1564922.01</SampleName>
      <Version>0</Version>
      <Sample>
        <FM_Id>ORD-1640271-01</FM_Id>
        <SampleId>US1564922.01</SampleId>
        <BlockId>S112-18119A (PF23069)</BlockId>
        <TRFNumber>ORD-1640271-01</TRFNumber>
        <TestType>FoundationOne CDX</TestType>
        <SpecFormat>Slide Deck</SpecFormat>
        <ReceivedDate>2023-05-30</ReceivedDate>
        <processSites>
          <processSite address="150 Second St., 1st Floor, Cambridge, MA 02141" cliaNumber="22D2027531" locationID="1" locationName="Cambridge" processID="1" processName="LC" />
          <processSite address="150 Second St., 1st Floor, Cambridge, MA 02141" cliaNumber="22D2027531" locationID="1" locationName="Cambridge" processID="1" processName="Extracted DNA" />
        </processSites>
      </Sample>
      <PMI>
        <ReportId>ORD-1640271-01</ReportId>
        <MRN>40079638</MRN>
        <FullName>Tsai, Yung Chen</FullName>
        <FirstName>Yung Chen</FirstName>
        <LastName>Tsai</LastName>
        <SubmittedDiagnosis>Brain glioblastoma (GBM)</SubmittedDiagnosis>
        <Gender>Female</Gender>
        <DOB>1984-05-16</DOB>
        <OrderingMD>Yeh, Yi-Chen</OrderingMD>
        <OrderingMDId>109266</OrderingMDId>
        <Pathologist>Not Provided</Pathologist>
        <CopiedPhysician1 />
        <MedFacilName>Taipei Veterans General Hospital</MedFacilName>
        <MedFacilID>205872</MedFacilID>
        <SpecSite>Brain</SpecSite>
        <CollDate>2023-04-25</CollDate>
        <ReceivedDate>2023-05-30</ReceivedDate>
        <CountryOfOrigin>TW</CountryOfOrigin>
      </PMI>
      <PertinentNegatives>
        <PertinentNegative>
          <Gene>EGFR</Gene>
        </PertinentNegative>
        <PertinentNegative>
          <Gene>IDH1</Gene>
        </PertinentNegative>
        <PertinentNegative>
          <Gene>PDGFRA</Gene>
        </PertinentNegative>
      </PertinentNegatives>
      <Summaries alterationCount="16" clinicalTrialCount="20" resistiveCount="0" sensitizingCount="12" />
      <VariantProperties>
        <VariantProperty geneName="CDKN2A/B" isVUS="true" variantName="amplification,amplification" />
        <VariantProperty geneName="FANCG" isVUS="true" variantName="amplification" />
        <VariantProperty geneName="MTAP" isVUS="true" variantName="amplification" />
        <VariantProperty geneName="PAX5" isVUS="true" variantName="amplification" />
        <VariantProperty geneName="PIK3C2G" isVUS="true" variantName="Y1103fs*15" />
        <VariantProperty geneName="TEK" isVUS="true" variantName="amplification" />
      </VariantProperties>
      <priorTests />
      <Genes>
        <Gene>
          <Name>CD274 (PD-L1)</Name>
          <Include>true</Include>
          <Alterations>
            <Alteration>
              <Name>amplification</Name>
              <AlterationProperties>
                <AlterationProperty isEquivocal="false" name="amplification" />
              </AlterationProperties>
              <Interpretation>CD274 encodes the programmed cell death ligand 1 (PD-L1), also known as B7-H1, which is a cell surface molecule important for regulating the activity of T-cells through binding to various T-cell receptors. Although PD-L1 is a costimulatory molecule for naive T-cells, it can provide inhibitory signals to activated T-cells through interactions with the receptors PD-1 or CD80 (Keir et al., 2008; 18173375, Butte et al., 2007; 17629517). These signals can help PD-L1-expressing tumor cells evade immune detection by natural killer cells or T-cells (Benson et al., 2010; 20460501, Iwai et al., 2002; 12218188, Liu et al., 2007; 17363736). CD274 amplification is associated with positive PD-L1 protein expression in solid tumors (Huang et al., 2021; 32884129, Cancer Genome Atlas Research Network., 2014; 25079317, George et al., 2017; 27620277) and lymphomas (Ansell et al., 2015; 25482239, Green et al., 2010; 20628145). CD274 amplification has been observed in &lt;1% of CNS tumors in a retrospective pan-tumor study (Huang et al., 2021; 32884129). However, PD-L1 protein expression has been detected in 61-88% of GBM (Nduom et al., 2016; 26323609, Bergoff et al., 2015; 25355681, Preusser et al., 2015; 26501438) and in 86% (18/21) grade 3 gliomas (Berghoff et al., 2015; European Cancer Congress Abstract 2926). Apart from membranous PD-L1 staining, one study observed diffuse/fibrillary PD-L1 expression in a high fraction of GBM specimens (Bergoff et al., 2015; 25355681). PD-L1 protein positivity did not correlate with patient outcomes (Nduom et al., 2016; 26323609, Bergoff et al., 2015; 25355681), although membranous PD-L1 expression in at least 5% of tumor cells associated with shorter survival in the secondary analysis of one study (Nduom et al., 2016; 26323609), which is supported by a small dataset of 17 glioblastoma cases (Liu et al., 2013; 23986257). The prognostic role of high PD-L1 gene expression in glioma and GBM is not clear. Two studies have reported a significant correlation with shorter survival (Wang et al., 2016; 27999734, Nduom et al., 2016; 26323609), whereas another study observed no association (Bergoff et al., 2015; 25355681). Preclinical data in murine GBM models suggest that anti-PD-1 blockade alone or combined with other therapies may be an effective therapeutic strategy against malignant gliomas (Reardon et al., 2016; 26546453, Zeng et al., 2013; 23462419, Wainwright et al., 2014; 24691018). On the basis of strong clinical evidence, CD274 amplification and PD-L1 overexpression may predict sensitivity to antibodies targeting PD-L1 or PD-1. Patients with high tumor PD-L1 expression across multiple solid tumor types have exhibited improved clinical benefit with the PD-L1 antibodies atezolizumab (Martin-Liberal et al., 2015; ESMO Symposium on Immuno-Oncology Abstract 24P, Fehrenbacher et al., 2016; 26970723, Herbst et al., 2014; 25428504), toripalimab (Jiang et al., 2021; EMSO Abstract 1310P, Tang et al., 2020; 32321714, Tang et al., 2021; ASCO Abstract e21522, Xu et al., 2019; ASCO Abstract 4021, Wang et al., 2019; 31236579, Xu et al., 2021; 33345750, Yonglong et al., 2021; 34678907, Xu et al., 2021; ASCO Abstract LBA2, Mai et al., 2021; 34341578, Wang et al., 2021; 33492986, Sheng et al., 2021; 34740921), and durvalumab (Powles et al., 2017; ASCO Genitourinary Abstract 286, Massard et al., 2016; 27269937, Bais et al., 2017; AACR Abstract 3720/5, Garassino et al., 2016; IASLC Abstract PLO4a.03, Segal et al., 2015; ASCO Abstract 3011, Rebelatto et al., 2015; ASCO Abstract 8033). The PD-1 antibodies pembrolizumab, nivolumab (alone or in combination with ipilimumab), and tislelizumab have elicited significant clinical responses for patients with solid tumors (Kefford et al., 2014; ASCO Abstract 3005, Groschel et al., 2016; 27900363, Hellman et al., 2017; ASCO Abstract 3001, Sharma et al., 2020; 3291612, Wolchok et al., 2017; ASCO Abstract 9505, Motzer et al., 2018; 29562145, Escudier et al., 2017; ESMO Abstract LBA5, Shen et al., 2022; 35442766) and for patients with Hodgkin lymphoma, a tumor type that harbors frequent PD-L1 copy number gains (Ansell et al., 2015; ASH Abstract 583, Ansell et al., 2015; 25482239). However, studies evaluating nivolumab for patients with urothelial carcinoma or tislelizumab plus sitravatinib for patients with non-small cell lung cancer (NSCLC) have shown no correlation between clinical benefit and PD-L1 expression levels (Sharma et al., 2018; AACR abstract CT178, Qing et al., 2022; ESMO TAT abstract 2P). A Phase 1 trial evaluating bintrafusp alfa, a fusion protein targeting TGF-beta and PD-L1, reported ORRs of 37% (10/27) and 86% (6/7) for patients with NSCLC characterized as PD-L1-positive or having high PD-L1 expression, respectively (Paz-Ares et al., 2020; 32173464). Preclinical studies have demonstrated that JAK2 amplification regulates PD-L1 expression (Green et al., 2010; 20628145, Derenzini et al., 2011; 22829094); therefore, JAK2 inhibitors such as ruxolitinib may also be relevant for patients with PD-L1 amplification.</Interpretation>
              <Include>true</Include>
              <ClinicalTrialNote>CD274 (PD-L1) amplification or rearrangements that disrupt the 3' untranslated region (UTR) may promote PD-1 signaling and inhibit the antitumor immune response. Antibodies that block the interaction of PD-L1 and PD-1 (alone, in combination with anti-CTLA-4, or bispecific PD-1/CTLA-4 antibodies) may therefore be beneficial to release the antitumor immune response. Furthermore, JAK2 inhibitors may be relevant, as they may reduce PD-L1 expression.</ClinicalTrialNote>
              <Therapies>
                <Therapy>
                  <Name />
                  <GenericName>Retifanlimab</GenericName>
                  <FDAApproved>false</FDAApproved>
                  <Rationale>&lt;p&gt;&lt;b&gt;Approved Indications:&lt;/b&gt; Retifanlimab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, reducing inhibition of the antitumor response. It is FDA approved to treat patients with Merkel cell carcinoma. Please see the drug label for full prescribing information. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Gene Association:&lt;/b&gt; Activation of PDCD1LG2 may lead to overexpression of PD-L2 and may confer sensitivity to PD-1 inhibitors such as retifanlimab. CD274 alterations, such as amplification or rearrangement, may lead to overexpression of PD-L1 and predict sensitivity to PD-L1-blocking antibodies such as retifanlimab based on clinical evidence in multiple solid tumor types (Oaknin et al., 2020; 33001143, Subramanian et al., 2020; ESMO Abstract 1399P, Andre et al., 2021; ASCO GI Abstract 9, Gabrail et al., 2019; ASCO Abstract 2560). &lt;/p&gt; &lt;p&gt;&lt;b&gt;Supporting Data:&lt;/b&gt; For patients with recurrent glioblastoma, a Phase 2 study of retifanlimab plus bevacizumab and hypofractionated radiotherapy showed an ORR of 58% (14/24), median PFS of 7.0 months, and median OS of 12.2 months (Butt et al., 2022; SNO Abstract CTIM-10). In the same setting, another Phase 2 study of retifanlimab plus the GITR agonist INCAGN01876 and fractionated stereotactic radiotherapy reported no responses, a DCR of 56% (9/16), median PFS of 3.9 months, and median OS of 9.8 months (Bagley et al., 2022; SNO Abstract CTIM-35). &lt;/p&gt;</Rationale>
                  <ApprovedUses />
                  <Effect>Sensitizing</Effect>
                  <Include>true</Include>
                  <IncludeInSummary>true</IncludeInSummary>
                  <ReferenceLinks />
                </Therapy>
                <Therapy>
                  <Name />
                  <GenericName>Durvalumab</GenericName>
                  <FDAApproved>false</FDAApproved>
                  <Rationale>&lt;p&gt;&lt;b&gt;Approved Indications:&lt;/b&gt; Durvalumab is a monoclonal antibody that binds to PD-L1 and blocks its interaction with PD-1 to enhance antitumor immune responses. It is FDA approved to treat patients with non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and biliary tract cancer. Please see the drug label for full prescribing information. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Gene Association:&lt;/b&gt; CD274 alterations, such as amplification or rearrangement, may lead to overexpression of PD-L1 and predict sensitivity to PD-L1-blocking antibodies such as durvalumab based on clinical evidence in multiple solid tumor types (Schmid et al., 2016; ASCO Abstract 11506, Disis et al., 2016; ASCO Abstract 5533, Dirix et al., 2016; SABCS Abstract S1-04, Verschraegen et al., 2016; ASCO Abstract 9036, Gulley et al., 2015; ECC Abstract 3090, Powles et al., 2017; ASCO Genitourinary Abstract 286, Segal et al., 2015; ASCO Abstract 3011, Rebelatto et al., 2015; ASCO Abstract 8033, Bais et al., 2017; AACR Abstract 3720/5, Garassino et al., 2016; IASLC Abstract PLO4a.03)(Fehrenbacher et al., 2016; 26970723, Herbst et al., 2015; 25680375, Massard et al., 2016; 27269937). Amplification of PDCD1LG2, which is often co-amplified with CD274, may lead to PD-L2 overexpression and predict sensitivity to PD-L1-blocking antibodies such as durvalumab. Although durvalumab does not block the interaction between PD-L2 and PD-1, clinical evidence in multiple solid tumor types suggests that PD-L2 expression may correlate with improved OS and response to the similar PD-L1-blocking antibody atezolizumab (Schmid et al., 2016; ASCO Abstract 11506, Herbst et al., 2015; 25680375, Fehrenbacher et al., 2016; 26970723). &lt;/p&gt; &lt;p&gt;&lt;b&gt;Supporting Data:&lt;/b&gt; A Phase 2 study of durvalumab combined with standard radiotherapy followed by durvalumab monotherapy for patients with newly diagnosed unmethylated MGMT glioblastoma after resection reported a 12-month OS of 60.0% (24/40) and median OS of 15.1 months (Reardon et al., 2019; ASCO Abstract 2032). A Phase 2 study of durvalumab and 10 or 3 mg/kg bevacizumab (cohorts B2 and B3, respectively) for the treatment of bevacizumab-naive recurrent glioblastoma reported 9.1% (3/33) PRs in both cohorts and a 6-month PFS rate of 15.2% and 21.1%, respectively (Reardon et al., 2018; SNO Abstract ATIM-38). A Phase 2 study of durvalumab combined with bevacizumab for the treatment of bevacizumab-refractory recurrent glioblastoma reported 50.0% (11/22) of patients had PFS greater than 8 weeks and 36.4% (8/22) of patients had OS greater than 22 weeks (Reardon et al., 2017; SNO Abstract ATIM-12). &lt;/p&gt;</Rationale>
                  <ApprovedUses />
                  <Effect>Sensitizing</Effect>
                  <Include>true</Include>
                  <IncludeInSummary>true</IncludeInSummary>
                  <ReferenceLinks />
                </Therapy>
                <Therapy>
                  <Name />
                  <GenericName>Cemiplimab</GenericName>
                  <FDAApproved>false</FDAApproved>
                  <Rationale>&lt;p&gt;&lt;b&gt;Approved Indications:&lt;/b&gt; Cemiplimab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with the ligands PD-L1 and PD-L2 to enhance antitumor immune responses. It is FDA approved to treat patients with non-small cell lung cancer (NSCLC), cutaneous squamous cell carcinoma, or basal cell carcinoma. Please see the drug label for full prescribing information. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Gene Association:&lt;/b&gt; Amplification of CD274 or PDCD1LG2 may lead to overexpression of PD-1 ligand(s). In multiple cancer types, PD-L1 expression correlated positively with PD-1 (on lymphocytes) and PD-L2 expression as well as improved clinical benefit in response to anti-PD-1 immunotherapies (Kefford et al., 2014; ASCO Abstract 3005, Garon et al., 2015; 25891174, Herbst et al., 2015; 26712084, Taube et al., 2014; 24714771, Bellone et al., 2015; 29351920, Topalian et al., 2012; 22658127, Ansell et al., 2015; ASH Abstract 583, Ansell et al., 2015; 25482239) and may predict sensitivity to cemiplimab. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Supporting Data:&lt;/b&gt; A Phase 1/2 trial of cemiplimab in combination with the investigational immunotherapeutic agents INO-5401 and INO-9012 reported a 12-month OS of 84% for patients with glioblastoma multiforme (GBM) and unmethylated-MGMT status (Reardon et al., 2020; ASCO Abstract 2514). In the neoadjuvant setting, cemiplimab was also associated with clinical benefit for 1 patient with high-grade glioma following a third recurrence and subsequent resection in a case report (McCord et al., 2021; 34250480). Cemiplimab has been studied primarily in advanced cutaneous squamous cell carcinoma (CSCC), where it elicited a combined ORR of 48% (41/85) in Phase 1 and 2 studies (Migden et al., 2018; 29863979). A Phase 2 trial of cemiplimab in patients with basal cell carcinoma (BCC) reported ORRs of 31% (5 CRs and 21 PRs) in patients with locally advanced BCC and 21% (6 PRs) in patients with metastatic BCC (Stratigos et al., 2020; EMSO Abstract LBA47, Lewis et al. 2020; doi: 10.1136/jitc-2020-SITC2020.0428). The Phase 3 EMPOWER-Lung 1 trial for advanced non-small cell lung cancer (NSCLC) with PD-L1 expression ≥50% reported that cemiplimab is associated with improved PFS (8.2 vs. 5.7 months), OS (not reached vs. 14.2 months), and ORR (37% vs. 21%) compared with chemotherapy (Sezer et al., 2020; ESMO Abstract LBA52). &lt;/p&gt;</Rationale>
                  <ApprovedUses />
                  <Effect>Sensitizing</Effect>
                  <Include>true</Include>
                  <IncludeInSummary>true</IncludeInSummary>
                  <ReferenceLinks />
                </Therapy>
                <Therapy>
                  <Name />
                  <GenericName>Pembrolizumab</GenericName>
                  <FDAApproved>true</FDAApproved>
                  <Rationale>&lt;p&gt;&lt;b&gt;Approved Indications:&lt;/b&gt; Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with the ligands PD-L1 and PD-L2 to enhance antitumor immune responses. It is FDA approved for patients with tumor mutational burden-high (≥10 Muts/Mb), microsatellite instability-high (MSI-H), or MMR-deficient (dMMR) solid tumors; as monotherapy for PD-L1-positive head and neck squamous cell cancer (HNSCC), cervical cancer, or esophageal cancer; and in combination with chemotherapy for PD-L1-positive triple-negative breast cancer (TNBC) or cervical cancer. It is also approved in various treatment settings as monotherapy for patients with non-small cell lung cancer (NSCLC), melanoma, HNSCC, urothelial carcinoma, hepatocellular carcinoma, Merkel cell carcinoma, cutaneous squamous cell carcinoma, MSI-H or dMMR endometrial carcinoma, classical Hodgkin lymphoma, or primary mediastinal large B-cell lymphoma; and in combination with chemotherapy or targeted therapy for NSCLC, HNSCC, esophageal or gastroesophageal junction cancer, renal cell carcinoma, TNBC, urothelial carcinoma, or endometrial carcinoma that is not MSI-H or dMMR. Please see the drug label for full prescribing information. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Gene Association:&lt;/b&gt; Amplification of CD274 or PDCD1LG2 may lead to overexpression of PD-1 ligand(s) and may predict sensitivity to pembrolizumab. Treatment with pembrolizumab has resulted in a lasting CR in a patient with CD274-amplified DLBCL (Godfrey et al., 2019; 30910787) and in a lasting PR in a patient with CD274-amplified cancer of unknown primary (Gröschel et al., 2016; 27900363). PD-L1 expression is associated with significantly prolonged median OS for patients with EGFR/ALK wildtype advanced NSCLC treated with pembrolizumab compared with chemotherapy (Mok et al 2019; 30955977, Reck et al., 2019; 30620668, Herbst et al., 2016; 26712084). One trial in patients with melanoma observed an improved objective response rate (51% vs. 6%) and PFS (12 vs. 3 months) for PD-L1 positive compared to PD-L1 negative tumors (Kefford et al., 2014; ASCO Abstract 3005). Furthermore, PD-L1 expression correlated positively with expression of PD-1 (on lymphocytes) and PD-L2, as well as with objective response to the anti-PD-1 antibody nivolumab in various advanced solid tumors (Taube et al., 2014; 24714771). &lt;/p&gt; &lt;p&gt;&lt;b&gt;Supporting Data:&lt;/b&gt; A Phase 2 study of patients with bevacizumab-naïve, recurrent glioblastoma (GBM) reported that single-agent pembrolizumab had limited activity; similar median PFS (1.4 vs. 4.1 months) and OS (10.3 vs. 8.8 months) were reported for pembrolizumab monotherapy and pembrolizumab combined with bevacizumab, respectively (Reardon et al., 2018; ASCO Abstract 2006). Similar PFS (2.8 months) and OS (14.4 months) were reported for bevacizumab-naïve, recurrent PD-L1-positive GBM (≥1% in tumor or immune cells) treated with pembrolizumab monotherapy in the Phase 1b KEYNOTE-028 study (Reardon et al., 2016; SNO Abstract ATIM-35). Administration of pembrolizumab both before and after surgery in the treatment of recurrent GBM achieved lasting response (&gt;34 months) for 13.3% (2/15) of patients in a single-arm study (De Groot et al., 2018; ASCO Abstract 2008). Combination of pembrolizumab with bevacizumab and stereotactic radiation in 23 adults with recurrent GBM or anaplastic astrocytoma elicited durable responses (CR or PR ≥6 months) in 53% of patients (Sahebjam et al., 2017; SNO Abstract ATIM-18). &lt;/p&gt;</Rationale>
                  <ApprovedUses />
                  <Effect>Sensitizing</Effect>
                  <Include>true</Include>
                  <IncludeInSummary>true</IncludeInSummary>
                  <ReferenceLinks />
                </Therapy>
                <Therapy>
                  <Name />
                  <GenericName>Nivolumab</GenericName>
                  <FDAApproved>false</FDAApproved>
                  <Rationale>&lt;p&gt;&lt;b&gt;Approved Indications:&lt;/b&gt; Nivolumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, reducing inhibition of the antitumor immune response. It is FDA approved as a monotherapy in various treatment settings for patients with melanoma, renal cell carcinoma (RCC), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), urothelial carcinoma, colorectal cancer (CRC), classical Hodgkin lymphoma (cHL), gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma or squamous cell carcinoma (ESCC). It is also approved in combination with chemotherapy to treat ESCC, in combination with cabozantinib to treat RCC, and in combination with relatlimab to treat melanoma. Please see the drug label for full prescribing information. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Gene Association:&lt;/b&gt; Amplification of CD274 or PDCD1LG2 may lead to overexpression of PD-1 ligand(s) and may predict sensitivity to nivolumab. In various advanced solid tumors, including melanoma, lung, kidney, prostate, and colorectal cancer, PD-L1 expression correlated positively with PD-1 (on lymphocytes) and PD-L2 expression as well as with objective response to nivolumab (Taube et al., 2014; 24714771, Topalian et al., 2012; 22658127). &lt;/p&gt; &lt;p&gt;&lt;b&gt;Supporting Data:&lt;/b&gt; The CheckMate 143 Phase 3 trial comparing nivolumab monotherapy to bevacizumab in recurrent glioblastoma (GBM) reported similar PFS (1.5 vs. 3.5 months) and median OS (9.8 vs. 10.0 months), although nivolumab elicited a numerically longer duration of response (11.1 vs. 5.3 months) (Reardon et al., 2020; 32437507). Exploratory CheckMate-143 cohorts showed combination of nivolumab and radiotherapy, with or without temozolomide, to be well tolerated (Lim et al., 2017; ESMO Abstract 325O); these regimens are being further evaluated in the CheckMate-548 (NCT02667587) study in newly diagnosed GBM. Retrospective studies in recurrent GBM or high-grade glioma reported stable disease rates of 56% (9/16) to 72% (36/50) for nivolumab alone or in combination with bevacizumab, with Grade 3/4 treatment-related AEs in 8% (4/50) to 13% (2/16) of patients (Chamberlain and Kim, 2017; 28500559, Mantica et al., 2018; 29779086). Biallelic mismatch repair deficiency (bMMRD)-associated GBMs harbor extraordinarily high mutational loads (Shlien et al., 2015; 25642631, Bouffet et al., 2016; 27001570), and three pediatric patients with bMMRD-associated GBM achieved clinically and radiologically significant responses to nivolumab monotherapy (Bouffet et al., 2016; 27001570, AlHarbi et al., 2018; 30104292). An adult with previously treated GBM experienced tumor shrinkage and disease stabilization for 2 years after pseudoprogression on nivolumab (Roth et al., 2017; 28039369). In a Phase 1 study, three patients with progressive GBM benefited from regimens combining nivolumab with surgery and the VEGFR2-targeting vaccine VXM01 (Wick et al., 2018; ASCO Abstract 2017). &lt;/p&gt;</Rationale>
                  <ApprovedUses />
                  <Effect>Sensitizing</Effect>
                  <Include>true</Include>
                  <IncludeInSummary>true</IncludeInSummary>
                  <ReferenceLinks />
                </Therapy>
                <Therapy>
                  <Name />
                  <GenericName>Nivolumab + Ipilimumab</GenericName>
                  <FDAApproved>false</FDAApproved>
                  <Rationale>&lt;p&gt;&lt;b&gt;Approved Indications:&lt;/b&gt; Nivolumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, reducing inhibition of the antitumor immune response, and ipilimumab is a cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody. The combination is FDA approved in various treatment settings for patients with melanoma, renal cell carcinoma (RCC), non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), pleural mesothelioma, and esophageal squamous cell carcinoma (ESCC). Furthermore, nivolumab is approved in combination with ipilimumab to treat patients with mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer (CRC). Please see the drug label for full prescribing information. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Gene Association:&lt;/b&gt; On the basis of clinical evidence for PD-L1 overexpression across various solid tumor types, alterations that lead to activation of CD274 may predict sensitivity to combination nivolumab and ipilimumab (Hellman et al., 2017; ASCO Abstract 3001, Sharma et al., 2020; 32916128, Larkin et al., 2015; 26027431, Motzer et al., 2018; 29562145, Wolchok et al., 2017; ASCO Abstract 9505). &lt;/p&gt; &lt;p&gt;&lt;b&gt;Supporting Data:&lt;/b&gt; The Phase 1 CheckMate 143 study for patients with recurrent glioblastoma reported ORRs of 0-10%, median PFS of 1.5-2.1 months, and median OS of 7.3-9.2 months following treatment with nivolumab and ipilimumab at different doses (Omuro et al., 2018; 29106665). A retrospective study of pediatric patients with recurrent or refractory CNS tumors treated with nivolumab combined with ipilimumab reported objective responses in 30% (3/9) of the patients (Cacciotti et al., 2020; 32627129). &lt;/p&gt;</Rationale>
                  <ApprovedUses />
                  <Effect>Sensitizing</Effect>
                  <Include>true</Include>
                  <IncludeInSummary>true</IncludeInSummary>
                  <ReferenceLinks />
                </Therapy>
                <Therapy>
                  <Name />
                  <GenericName>Dostarlimab</GenericName>
                  <FDAApproved>true</FDAApproved>
                  <Rationale>&lt;p&gt;&lt;b&gt;Approved Indications:&lt;/b&gt; Dostarlimab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, reducing inhibition of the antitumor response. It is FDA approved to treat patients with mismatch repair deficient recurrent or advanced endometrial cancer or solid tumors. Please see the drug label for full prescribing information. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Gene Association:&lt;/b&gt; Activation of PDCD1LG2 may lead to overexpression of PD-L2 and may confer sensitivity to PD-1 inhibitors such as dostarlimab. CD274 alterations, such as amplification or rearrangement, may lead to overexpression of PD-L1 and predict sensitivity to PD-L1-blocking antibodies such as dostarlimab based on clinical evidence in multiple solid tumor types (Oaknin et al., 2020; 33001143, Subramanian et al., 2020; ESMO Abstract 1399P, Andre et al., 2021; ASCO GI Abstract 9, Gabrail et al., 2019; ASCO Abstract 2560). &lt;/p&gt; &lt;p&gt;&lt;b&gt;Supporting Data:&lt;/b&gt; Clinical data on the efficacy of dostarlimab for the treatment of CNS tumors are limited (PubMed, Jan 2023). Dostarlimab has been studied primarily in recurrent and advanced mismatch repair-deficient (dMMR) endometrial and non-endometrial cancers (Andre et al., 2021; ASCO GI Abstract 9, Oaknin et al., 2020; 33001143, Berton et al., 2021; ASCO Abstract 2564). In the Phase 1 GARNET trial, single-agent dostarlimab elicited an ORR of 39% (41/106) and an immune-related ORR of 46% (50/110) for patients with non-endometrial dMMR solid tumors (Andre et al., 2021; ASCO GI Abstract 9, Andre et al., 2021; ESMO GI Abstract SO-9). &lt;/p&gt;</Rationale>
                  <ApprovedUses />
                  <Effect>Sensitizing</Effect>
                  <Include>true</Include>
                  <IncludeInSummary>true</IncludeInSummary>
                  <ReferenceLinks />
                </Therapy>
                <Therapy>
                  <Name />
                  <GenericName>Atezolizumab</GenericName>
                  <FDAApproved>false</FDAApproved>
                  <Rationale>&lt;p&gt;&lt;b&gt;Approved Indications:&lt;/b&gt; Atezolizumab is a monoclonal antibody that binds to PD-L1 and blocks its interaction with PD-1 to enhance antitumor immune responses. It is FDA approved to treat patients with non-small cell lung cancer (NSCLC) as well as adult and pediatric patients 2 years and older with alveolar soft part sarcoma, depending on treatment setting. Atezolizumab is also approved in combination with other therapies to treat patients with non-squamous NSCLC lacking EGFR or ALK alterations, small cell lung cancer, hepatocellular carcinoma, and BRAF V600-positive melanoma. Please see the drug label for full prescribing information. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Gene Association:&lt;/b&gt; CD274 alterations, such as amplification or rearrangements, that lead to overexpression of PD-L1 may predict sensitivity to atezolizumab based on clinical evidence in multiple solid tumor types (Schmid et al., 2016; ASCO Abstract 11506)(Fehrenbacher et al., 2016; 26970723, Herbst et al., 2015; 25680375). Amplification of PDCD1LG2, which is often co-amplified with CD274, may lead to PD-L2 overexpression and predict sensitivity to anti-PD-L1 inhibitors such as atezolizumab. Although atezolizumab does not block the interaction between PD-L2 and PD-1, clinical evidence in multiple solid tumor types suggests that PD-L2 expression may correlate with improved OS and response to atezolizumab (Schmid et al., 2016; ASCO Abstract 11506, Herbst et al., 2015; 25680375, Fehrenbacher et al., 2016; 26970723). &lt;/p&gt; &lt;p&gt;&lt;b&gt;Supporting Data:&lt;/b&gt; In a Phase 1a of atezolizumab for patients with glioblastoma (GBM) who had failed prior radiotherapy and/or temazolomide, an objective response rate (ORR) of 6% (1/16) was observed, with 1 patient achieving a partial response (PR) for 16 months and 3 others achieving stable disease (SD); of these 4 patients, all were microsatellite stable, 3 (including the patient with a PR) harbored IDH1 R132H mutations, and 2 experienced an overall survival (OS) of &gt;16 months (Lukas et al., 2018; 30073642). A patient with POLE L424V-mutated GBM enrolled in this study achieved an OS of ~18 months (Lukas et al., 2018; 30073642). In a retrospective analysis of 17 solid tumor types (comprised of 47% NSCLC, 40% mUC, and 13% encompassing 15 other solid tumors, including GBM), a TMB of ≥16 muts/Mb associated with an improved ORR and duration of response to atezolizumab compared with chemotherapy alone (Legrand et al., 2018; ASCO Abstract 12000). Atezolizumab has been studied primarily for treating non-small cell lung cancer (NSCLC) (Smith et al., 2016; ASCO Abstract 9028, Mazieres et al., 2016; ASCO Abstract 9032, Besse et al., 2015; ECC Abstract 16LBA, Spigel et al., 2015; ASCO Abstract 8028, Fehrenbacher et al., 2016; 26970723, Herbst et al., 2014; 25428504) and urothelial carcinoma (Balar et al., 2016; ASCO Abstract LBA4500, Dreicer et al., 2016; ASCO Abstract 4515) (Rosenberg et al., 2016; 26952546, Powles et al., 2014; 25428503). A study of atezolizumab as monotherapy for patients with advanced solid tumors reported a median PFS of 18 weeks and an ORR of 21%, including confirmed responses in 26% (11/43) of melanomas, 13% (7/56) of renal cell carcinomas (RCC) and 17% (1/6) of colorectal cancers (CRCs)(Herbst et al., 2014; 25428504). As a single-agent therapy in genomically unselected young patients (&lt;30 years old) with relapsed or refractory cancers, atezolizumab elicited an ORR of 1.5% (1/67) for patients with solid tumors, with similar safety and pharmacokinetics as seen in adults (Geoerger et al., 2020; 31780255). A Phase 1a study of atezolizumab reported an ORR of 15% (9/62), a median PFS of 5.6 months, and a median OS of 28.9 months for patients with clear cell renal cell carcinoma (ccRCC) (McDermott et al., 2016; 26755520). A Phase 1b study evaluated atezolizumab combined with nab-paclitaxel for patients with previously treated metastatic triple-negative breast cancer (mTNBC) and reported confirmed objective responses for 42% (10/24) of patients; no dose-limiting toxicities were observed (Adams et al., 2016; ASCO Abstract 1009). A Phase 1b study that evaluated atezolizumab in combination with the MEK inhibitor cobimetinib for advanced solid tumors reported an ORR of 8.3% (7/84) for patients with CRC, 41% (9/22) for patients with melanoma, 18% (5/28) for patients with NSCLC, and 19% (3/16) for patients with other tumors (ovarian cancer, clear-cell sarcoma, and RCC); there was no association between BRAF or KRAS mutation status and response rate in any disease setting, and no dose-limiting toxicities were encountered (Hellmann et al., 2019; 30918950, Bendell et al., 2016; ASCO Abstract 3502). &lt;/p&gt;</Rationale>
                  <ApprovedUses />
                  <Effect>Sensitizing</Effect>
                  <Include>true</Include>
                  <IncludeInSummary>true</IncludeInSummary>
                  <ReferenceLinks />
                </Therapy>
                <Therapy>
                  <Name />
                  <GenericName>Avelumab</GenericName>
                  <FDAApproved>false</FDAApproved>
                  <Rationale>&lt;p&gt;&lt;b&gt;Approved Indications:&lt;/b&gt; Avelumab is a monoclonal antibody that binds to PD-L1 and blocks its interaction with PD-1 in order to enhance antitumor immune responses. It is FDA approved to treat patients 12 years and older with Merkel cell carcinoma, or for urothelial carcinoma in various treatment settings. The combination of avelumab and axitinib is FDA approved for patients with renal cell carcinoma (RCC). Please see the drug label for full prescribing information. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Gene Association:&lt;/b&gt; CD274 alterations, such as amplification or rearrangement, may lead to overexpression of PD-L1 and predict sensitivity to PD-L1-blocking antibodies such as avelumab based on clinical evidence in multiple solid tumor types (Schmid et al., 2016; ASCO Abstract 11506, Disis et al., 2016; ASCO Abstract 5533, Dirix et al., 2016; SABCS Abstract S1-04, Verschraegen et al., 2016; ASCO Abstract 9036, Gulley et al., 2015; ECC Abstract 3090)(Fehrenbacher et al., 2016; 26970723, Herbst et al., 2015; 25680375). Amplification of PDCD1LG2, which is often co-amplified with CD274, may lead to PD-L2 overexpression and predict sensitivity to PD-L1-blocking antibodies such as avelumab. Although avelumab does not block the interaction between PD-L2 and PD-1, clinical evidence in multiple solid tumor types suggests that PD-L2 expression may correlate with improved OS and response to the similar PD-L1-blocking antibody atezolizumab (Schmid et al., 2016; ASCO Abstract 11506, Herbst et al., 2015; 25680375, Fehrenbacher et al., 2016; 26970723). &lt;/p&gt; &lt;p&gt;&lt;b&gt;Supporting Data:&lt;/b&gt; A Phase 2 open-label study of avelumab monotherapy for the treatment of newly diagnosed glioblastoma after treatment with combined radiotherapy and temozolomide reported an ORR (iRANO) of 50.0% (2 CR, 1 PR, 1 SD) and median PFS of 11.9 months (Jacques et al., 2019; ASCO Abstract e13751). A Phase 2 study of avelumab with hypofractionated radiotherapy for the treatment of IDH-mutated glioblastoma after radiotherapy and temozolomide reported 1 out of 6 SD as best response, median PFS of 4.2 months, and median OS of 10.1 months (Kurz et al., 2019; SNO Abstract ATIM-37). A Phase 2 open-label study of axitinib combined with avelumab for the treatment of recurrent glioblastoma following surgery, radiotherapy, and temozolomide treatment reported an ORR (iRANO) of 41%, 6-month PFS of 18%, and median OS of 26 weeks (Neyns et al., 2019; ASCO Abstract 2034). &lt;/p&gt;</Rationale>
                  <ApprovedUses />
                  <Effect>Sensitizing</Effect>
                  <Include>true</Include>
                  <IncludeInSummary>true</IncludeInSummary>
                  <ReferenceLinks />
                </Therapy>
              </Therapies>
              <ReferenceLinks />
              <ClinicalTrialLinks>
                <ClinicalTrialLink nctId="NCT04237649">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT04047862">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT05166577">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT03530397">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT03821935">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT04215978">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT05024214">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT03744468">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT04892498">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT05142423">
                  <Include>true</Include>
                </ClinicalTrialLink>
              </ClinicalTrialLinks>
            </Alteration>
          </Alterations>
          <ReferenceLinks />
        </Gene>
        <Gene>
          <Name>NF1</Name>
          <Include>true</Include>
          <Alterations>
            <Alteration>
              <Name>R1276*</Name>
              <AlterationProperties>
                <AlterationProperty dnaFraction="51.18" isEquivocal="false" name="R1276*" />
              </AlterationProperties>
              <Interpretation>NF1 encodes neurofibromin, a GTPase-activating protein (GAP) that is a key negative regulator of the RAS signaling pathway (Hattori et al., 1991; 1904223). Neurofibromin acts as a tumor suppressor by repressing RAS signaling (Morcos et al., 1996; 8628317). Alterations such as seen here may disrupt NF1 function or expression (Ballester et al., 1990; 2121371, Xu et al., 1990; 2116237, Martin et al., 1990; 2121370, Thomas et al., 2012; 22807134, Skuse and Cappione, 1997; 9300663, Morcos et al., 1996; 8628317, Messiaen et al., 1999; 11258625, Ars et al., 2000; 10607834, Messiaen and Wimmer, 2005; 15863657, Poullet et al., 1994; 8264648). NF1 mutation has been observed in 5-6% of lower grade gliomas and 9-14% of glioblastoma multiforme (GBM) cases; homozygous deletion of NF1 was observed in 1% of lower grade gliomas and 2-3% of GBMs (Cancer Genome Atlas Research Network., 2015; 26061751, cBio-Johnson et al., 2014; 24336570, cBio-Brennan et al., 2013; 24120142, Cancer Genome Atlas Research Network., 2008; 18772890). Among GBM subtypes, NF1 mutation and loss were reported most frequently in the mesenchymal subtype, 37% (14/28) and 38% (21/55) of cases, respectively (Verhaak et al., 2010; 20129251). NF1 loss was significantly associated with decreased overall and disease-specific survival in patients with lower grade gliomas (II-III), but not in those with GBM (Vizcaino et al., 2015; 26190195). On the basis of clinical evidence in neurofibromatosis type 1-associated neurofibroma and malignant peripheral nerve sheath tumors (Dombi et al., 2016; 28029918, Schalkwijk et al., 2021; 33903938, Glassberg et al., 2020; ASPHO Abstract 2015, Coyne et al., 2020; ASCO Abstract 3612, McCowage et al., 2018; ASCO Abstract 10504, Mueller et al., 2020; SNO Abstract NFB-17, Hitchen et al., 2023; 36743881, Nagabushan et al., 2021; 33580196, Hones et al., 2022; 36192032), central nervous system tumors including glioma and astrocytoma (Fangusaro et al., 2019; 31151904, Manoharan et al., 2020; 32780261, Romo et al., 2019; SNO Abstract RARE-54, Awada et al., 2020; 33082744, Wisinski et al., 2023; 37053535), limited clinical evidence for MEK inhibitors in non-small cell lung cancer (NSCLC) (Middleton et al., 2020; 32669708, Wisinski et al., 2023; 37053535), and in combination with chemotherapy for biliary tract cancers (Lowery et al., 2019; 30563938), NF1 inactivation may predict sensitivity to MEK inhibitors such as cobimetinib, trametinib, binimetinib, and selumetinib. On the basis of limited clinical data (Lim et al., 2016; 26859683 , Weiss et al., 2015; 25314964, Janku et al., 2014; 24931142) and preclinical data (Johannessen et al., 2008; 18164202, Johannessen et al., 2005; 15937108), loss or inactivation of NF1 may predict sensitivity to mTOR inhibitors, including everolimus and temsirolimus. A preclinical study suggests that combined mTOR and MEK inhibition is effective in a model of NF1-deficient malignant peripheral nerve sheath tumors (MPNST) (Malone et al., 2014; 24913553). One or more of the NF1 variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with neurofibromatosis type 1 (ClinVar, Apr 2023)(Landrum et al., 2018; 29165669). Follow-up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. Germline mutations in NF1 cause the autosomal dominant disorder neurofibromatosis type 1, which is characterized in part by increased risk of developing various tumors, including sarcoma, glioma, breast carcinoma, and neuroendocrine and hematological neoplasms (Jett and Friedman, 2010; 20027112, Patil and Chamberlain, 2012; 22240541, Evans et al., 2012; 23036231). Estimates for the prevalence of the disorder in the general population range from 1:2,500 to 1:3,000 (Upadhyaya et al., 1995; 8544190, Williams et al., 2009; 19117870), and in the appropriate clinical context, germline testing of NF1 is recommended.</Interpretation>
              <Include>true</Include>
              <ClinicalTrialNote>On the basis of clinical evidence and strong preclinical evidence, NF1 inactivation may predict sensitivity to MEK inhibitors. Limited clinical data and strong preclinical data indicate that loss or inactivation of NF1 may also predict sensitivity to mTOR inhibitors.</ClinicalTrialNote>
              <Therapies>
                <Therapy>
                  <Name />
                  <GenericName>Cobimetinib</GenericName>
                  <FDAApproved>false</FDAApproved>
                  <Rationale>&lt;p&gt;&lt;b&gt;Approved Indications:&lt;/b&gt; Cobimetinib is a MEK inhibitor that is FDA approved to treat patients with histiocytic neoplasms. Please see the drug label for full prescribing information. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Gene Association:&lt;/b&gt; On the basis of clinical evidence in neurofibromatosis type 1 (NF1)-associated neurofibroma (Dombi et al., 2016; 28029918, Schalkwijk et al., 2021; 33903938, Glassberg et al., 2020; ASPHO Abstract 2015, Coyne et al., 2020; ASCO Abstract 3612, McCowage et al., 2018; ASCO Abstract 10504, Mueller et al., 2020; SNO Abstract NFB-17), malignant peripheral nerve sheath tumors (Hitchen et al., 2023; 36743881, Nagabushan et al., 2021; 33580196, Hones et al., 2022; 36192032), and central nervous system tumors including glioma, glioblastoma multiforme (GBM), and astrocytoma (Lucas et al., 2022; 35945463, Fangusaro et al., 2019; 31151904, Manoharan et al., 2020; 32780261, Romo et al., 2019; SNO Abstract RARE-54, Awada et al., 2020; 33082744, Wisinski et al., 2023; 37053535), NF1 inactivation may predict sensitivity to MEK inhibitors. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Supporting Data:&lt;/b&gt; MEK inhibitors have shown efficacy in several studies of low-grade and high-grade central nervous system (CNS) tumors. A Phase 2 study of selumetinib monotherapy for patients with NF1-associated low-grade glioma reported an ORR of 40%, with 10 patients experiencing PRs (Fangusaro et al., 2019; 31151904). An NCI-MATCH subprotocol of trametinib in NF1-mutated solid tumors reported 1 PR, 1 durable SD, and lack of benefit for 3 patients with glioblastoma multiforme (GBM) (Wisinski et al., 2023; 37053535). Additionally, case studies of trametinib monotherapy for NF1-associated brain tumors have reported PRs for 3 patients with low-grade glioma, 5 patients with astrocytoma, 1 patient with an optic pathway glioma, and 1 patient with a GBM (Manoharan et al., 2020; 32780261, Kondyli et al., 2018; 30097824, Ronsley et al., 2021; 33939292, Lucas et al., 2022; 35945463, Romo et al., 2019; SNO Abstract RARE-54, Awada et al., 2020; 33082744). A minor response was reported for 1 patient with glioma on cobimetinib (Trippett et al., 2022; 35715627). A Phase 1/2 study evaluating the use of cobimetinib for pediatric and young adult patients with relapsed or refractory solid tumors reported an ORR of 9.4% (3/32) among patients with low-grade glioma (Trippett et al., 2022; 35715627). A patient with anaplastic pleomorphic xanthoastrocytoma with leptomeningeal dissemination harboring an ATG7-RAF1 fusion exhibited a complete cytologic response and clinical benefit following treatment with cobimetinib (Touat et al., 2019; DOI: 10.1200/PO.18.00298). &lt;/p&gt;</Rationale>
                  <ApprovedUses />
                  <Effect>Sensitizing</Effect>
                  <Include>true</Include>
                  <IncludeInSummary>true</IncludeInSummary>
                  <ReferenceLinks />
                </Therapy>
                <Therapy>
                  <Name />
                  <GenericName>Selumetinib</GenericName>
                  <FDAApproved>false</FDAApproved>
                  <Rationale>&lt;p&gt;&lt;b&gt;Approved Indications:&lt;/b&gt; Selumetinib is a MEK inhibitor that is FDA approved to treat pediatric patients with neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas (PNs). Please see the drug label for full prescribing information. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Gene Association:&lt;/b&gt; On the basis of clinical evidence in neurofibromatosis type 1 (NF1)-associated neurofibroma (Dombi et al., 2016; 28029918, Schalkwijk et al., 2021; 33903938, Glassberg et al., 2020; ASPHO Abstract 2015, Coyne et al., 2020; ASCO Abstract 3612, McCowage et al., 2018; ASCO Abstract 10504, Mueller et al., 2020; SNO Abstract NFB-17), malignant peripheral nerve sheath tumors (Hitchen et al., 2023; 36743881, Nagabushan et al., 2021; 33580196, Hones et al., 2022; 36192032), and central nervous system tumors including glioma, glioblastoma multiforme (GBM), and astrocytoma (Lucas et al., 2022; 35945463, Fangusaro et al., 2019; 31151904, Manoharan et al., 2020; 32780261, Romo et al., 2019; SNO Abstract RARE-54, Awada et al., 2020; 33082744, Wisinski et al., 2023; 37053535), NF1 inactivation may predict sensitivity to MEK inhibitors. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Supporting Data:&lt;/b&gt; MEK inhibitors have shown efficacy in several studies of low-grade and high-grade central nervous system (CNS) tumors. A Phase 2 study of selumetinib monotherapy for patients with NF1-associated low-grade glioma reported an ORR of 40%, with 10 patients experiencing PRs (Fangusaro et al., 2019; 31151904). An NCI-MATCH subprotocol of trametinib in NF1-mutated solid tumors reported 1 PR, 1 durable SD, and lack of benefit for 3 patients with glioblastoma multiforme (GBM) (Wisinski et al., 2023; 37053535). Additionally, case studies of trametinib monotherapy for NF1-associated brain tumors have reported PRs for 3 patients with low-grade glioma, 5 patients with astrocytoma, 1 patient with an optic pathway glioma, and 1 patient with a GBM (Manoharan et al., 2020; 32780261, Kondyli et al., 2018; 30097824, Ronsley et al., 2021; 33939292, Lucas et al., 2022; 35945463, Romo et al., 2019; SNO Abstract RARE-54, Awada et al., 2020; 33082744). A minor response was reported for 1 patient with glioma on cobimetinib (Trippett et al., 2022; 35715627). Selumetinib has demonstrated clinical activity in low-grade glioma. A Phase 2 study of selumetinib for patients with low-grade glioma (LGG) reported 8/25 PRs for patients with BRAF alterations and 10/25 PRs for those with NF1-associated LGG (Fangusaro et al., 2019; 31151904); a Phase 1 study of selumetinib reported 5/25 PRs for patients with LGG (Banerjee et al., 2017; 28339824). A Phase 2 study of selumetinib for patients with tumors with activating alterations in the MAPK pathway evaluated 8 patients with high-grade glioma (HGG); 2 SDs and no objective responses were observed in this subset (Eckstein et al., 2022; 35363510). &lt;/p&gt;</Rationale>
                  <ApprovedUses />
                  <Effect>Sensitizing</Effect>
                  <Include>true</Include>
                  <IncludeInSummary>true</IncludeInSummary>
                  <ReferenceLinks />
                </Therapy>
                <Therapy>
                  <Name />
                  <GenericName>Trametinib</GenericName>
                  <FDAApproved>false</FDAApproved>
                  <Rationale>&lt;p&gt;&lt;b&gt;Approved Indications:&lt;/b&gt; Trametinib is a MEK inhibitor that is FDA approved as a monotherapy to treat patients with melanoma with BRAF V600E or V600K mutations. Please see the drug label for full prescribing information. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Gene Association:&lt;/b&gt; On the basis of clinical evidence in neurofibromatosis type 1 (NF1)-associated neurofibroma (Dombi et al., 2016; 28029918, Schalkwijk et al., 2021; 33903938, Glassberg et al., 2020; ASPHO Abstract 2015, Coyne et al., 2020; ASCO Abstract 3612, McCowage et al., 2018; ASCO Abstract 10504, Mueller et al., 2020; SNO Abstract NFB-17), malignant peripheral nerve sheath tumors (Hitchen et al., 2023; 36743881, Nagabushan et al., 2021; 33580196, Hones et al., 2022; 36192032), and central nervous system tumors including glioma, glioblastoma multiforme (GBM), and astrocytoma (Lucas et al., 2022; 35945463, Fangusaro et al., 2019; 31151904, Manoharan et al., 2020; 32780261, Romo et al., 2019; SNO Abstract RARE-54, Awada et al., 2020; 33082744, Wisinski et al., 2023; 37053535), NF1 inactivation may predict sensitivity to MEK inhibitors. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Supporting Data:&lt;/b&gt; MEK inhibitors have shown efficacy in several studies of low-grade and high-grade central nervous system (CNS) tumors. A Phase 2 study of selumetinib monotherapy for patients with NF1-associated low-grade glioma reported an ORR of 40%, with 10 patients experiencing PRs (Fangusaro et al., 2019; 31151904). An NCI-MATCH subprotocol of trametinib in NF1-mutated solid tumors reported 1 PR, 1 durable SD, and lack of benefit for 3 patients with glioblastoma multiforme (GBM) (Wisinski et al., 2023; 37053535). Additionally, case studies of trametinib monotherapy for NF1-associated brain tumors have reported PRs for 3 patients with low-grade glioma, 5 patients with astrocytoma, 1 patient with an optic pathway glioma, and 1 patient with a GBM (Manoharan et al., 2020; 32780261, Kondyli et al., 2018; 30097824, Ronsley et al., 2021; 33939292, Lucas et al., 2022; 35945463, Romo et al., 2019; SNO Abstract RARE-54, Awada et al., 2020; 33082744). A minor response was reported for 1 patient with glioma on cobimetinib (Trippett et al., 2022; 35715627). A study of 2 pediatric patients with optic astrocytomas harboring BRAF duplications reported clinical benefit in response to trametinib with reductions in tumor volume (56-66%) and treatment ongoing at 484 and 468 days (Miller et al., 2016; 28009226). A study of 5 patients with KIAA1549-BRAF-fusion-positive pilocytic astrocytoma reported 1 PR and 3 minor responses (Kondyli et al., 2018; 30097824) and, similarly, a patient with low-grade glioma harboring this fusion benefited from trametinib (Wagner et al., 2018; 29369501). A patient with pilocytic astrocytoma harboring an NFIA-RAF1 fusion who had progressed on multiple lines of prior treatment exhibited ongoing SD following treatment with trametinib (Yde et al., 2016; 27810072). Whereas frequent adverse events precluded a recommended Phase 2 dose and schedule for the combination of trametinib and everolimus in a Phase 1b trial for solid tumors (Tolcher et al., 2014; 25344362), a retrospective study for heavily pretreated patients with solid tumors reported tolerable regimens of the combination for 23/31 patients, with 16 patients treated &gt;3 months and evaluable patients achieving a median PFS of 6.5 months (Patterson et al., 2018; AACR Abstract 3891). &lt;/p&gt;</Rationale>
                  <ApprovedUses />
                  <Effect>Sensitizing</Effect>
                  <Include>true</Include>
                  <IncludeInSummary>true</IncludeInSummary>
                  <ReferenceLinks />
                </Therapy>
              </Therapies>
              <ReferenceLinks />
              <ClinicalTrialLinks>
                <ClinicalTrialLink nctId="NCT03239015">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT04803318">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT04985604">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT05125523">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT03905148">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT05580770">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT04720976">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT05036226">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT05159245">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT04817956">
                  <Include>true</Include>
                </ClinicalTrialLink>
              </ClinicalTrialLinks>
            </Alteration>
            <Alteration>
              <Name>Y489*</Name>
              <AlterationProperties>
                <AlterationProperty dnaFraction="27.53" isEquivocal="false" name="Y489*" />
              </AlterationProperties>
              <Interpretation>NF1 encodes neurofibromin, a GTPase-activating protein (GAP) that is a key negative regulator of the RAS signaling pathway (Hattori et al., 1991; 1904223). Neurofibromin acts as a tumor suppressor by repressing RAS signaling (Morcos et al., 1996; 8628317). Alterations such as seen here may disrupt NF1 function or expression (Ballester et al., 1990; 2121371, Xu et al., 1990; 2116237, Martin et al., 1990; 2121370, Thomas et al., 2012; 22807134, Skuse and Cappione, 1997; 9300663, Morcos et al., 1996; 8628317, Messiaen et al., 1999; 11258625, Ars et al., 2000; 10607834, Messiaen and Wimmer, 2005; 15863657, Poullet et al., 1994; 8264648). NF1 mutation has been observed in 5-6% of lower grade gliomas and 9-14% of glioblastoma multiforme (GBM) cases; homozygous deletion of NF1 was observed in 1% of lower grade gliomas and 2-3% of GBMs (Cancer Genome Atlas Research Network., 2015; 26061751, cBio-Johnson et al., 2014; 24336570, cBio-Brennan et al., 2013; 24120142, Cancer Genome Atlas Research Network., 2008; 18772890). Among GBM subtypes, NF1 mutation and loss were reported most frequently in the mesenchymal subtype, 37% (14/28) and 38% (21/55) of cases, respectively (Verhaak et al., 2010; 20129251). NF1 loss was significantly associated with decreased overall and disease-specific survival in patients with lower grade gliomas (II-III), but not in those with GBM (Vizcaino et al., 2015; 26190195). On the basis of clinical evidence in neurofibromatosis type 1-associated neurofibroma and malignant peripheral nerve sheath tumors (Dombi et al., 2016; 28029918, Schalkwijk et al., 2021; 33903938, Glassberg et al., 2020; ASPHO Abstract 2015, Coyne et al., 2020; ASCO Abstract 3612, McCowage et al., 2018; ASCO Abstract 10504, Mueller et al., 2020; SNO Abstract NFB-17, Hitchen et al., 2023; 36743881, Nagabushan et al., 2021; 33580196, Hones et al., 2022; 36192032), central nervous system tumors including glioma and astrocytoma (Fangusaro et al., 2019; 31151904, Manoharan et al., 2020; 32780261, Romo et al., 2019; SNO Abstract RARE-54, Awada et al., 2020; 33082744, Wisinski et al., 2023; 37053535), limited clinical evidence for MEK inhibitors in non-small cell lung cancer (NSCLC) (Middleton et al., 2020; 32669708, Wisinski et al., 2023; 37053535), and in combination with chemotherapy for biliary tract cancers (Lowery et al., 2019; 30563938), NF1 inactivation may predict sensitivity to MEK inhibitors such as cobimetinib, trametinib, binimetinib, and selumetinib. On the basis of limited clinical data (Lim et al., 2016; 26859683 , Weiss et al., 2015; 25314964, Janku et al., 2014; 24931142) and preclinical data (Johannessen et al., 2008; 18164202, Johannessen et al., 2005; 15937108), loss or inactivation of NF1 may predict sensitivity to mTOR inhibitors, including everolimus and temsirolimus. A preclinical study suggests that combined mTOR and MEK inhibition is effective in a model of NF1-deficient malignant peripheral nerve sheath tumors (MPNST) (Malone et al., 2014; 24913553). One or more of the NF1 variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with neurofibromatosis type 1 (ClinVar, Apr 2023)(Landrum et al., 2018; 29165669). Follow-up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. Germline mutations in NF1 cause the autosomal dominant disorder neurofibromatosis type 1, which is characterized in part by increased risk of developing various tumors, including sarcoma, glioma, breast carcinoma, and neuroendocrine and hematological neoplasms (Jett and Friedman, 2010; 20027112, Patil and Chamberlain, 2012; 22240541, Evans et al., 2012; 23036231). Estimates for the prevalence of the disorder in the general population range from 1:2,500 to 1:3,000 (Upadhyaya et al., 1995; 8544190, Williams et al., 2009; 19117870), and in the appropriate clinical context, germline testing of NF1 is recommended.</Interpretation>
              <Include>true</Include>
              <ClinicalTrialNote>On the basis of clinical evidence and strong preclinical evidence, NF1 inactivation may predict sensitivity to MEK inhibitors. Limited clinical data and strong preclinical data indicate that loss or inactivation of NF1 may also predict sensitivity to mTOR inhibitors.</ClinicalTrialNote>
              <Therapies>
                <Therapy>
                  <Name />
                  <GenericName>Cobimetinib</GenericName>
                  <FDAApproved>false</FDAApproved>
                  <Rationale>&lt;p&gt;&lt;b&gt;Approved Indications:&lt;/b&gt; Cobimetinib is a MEK inhibitor that is FDA approved to treat patients with histiocytic neoplasms. Please see the drug label for full prescribing information. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Gene Association:&lt;/b&gt; On the basis of clinical evidence in neurofibromatosis type 1 (NF1)-associated neurofibroma (Dombi et al., 2016; 28029918, Schalkwijk et al., 2021; 33903938, Glassberg et al., 2020; ASPHO Abstract 2015, Coyne et al., 2020; ASCO Abstract 3612, McCowage et al., 2018; ASCO Abstract 10504, Mueller et al., 2020; SNO Abstract NFB-17), malignant peripheral nerve sheath tumors (Hitchen et al., 2023; 36743881, Nagabushan et al., 2021; 33580196, Hones et al., 2022; 36192032), and central nervous system tumors including glioma, glioblastoma multiforme (GBM), and astrocytoma (Lucas et al., 2022; 35945463, Fangusaro et al., 2019; 31151904, Manoharan et al., 2020; 32780261, Romo et al., 2019; SNO Abstract RARE-54, Awada et al., 2020; 33082744, Wisinski et al., 2023; 37053535), NF1 inactivation may predict sensitivity to MEK inhibitors. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Supporting Data:&lt;/b&gt; MEK inhibitors have shown efficacy in several studies of low-grade and high-grade central nervous system (CNS) tumors. A Phase 2 study of selumetinib monotherapy for patients with NF1-associated low-grade glioma reported an ORR of 40%, with 10 patients experiencing PRs (Fangusaro et al., 2019; 31151904). An NCI-MATCH subprotocol of trametinib in NF1-mutated solid tumors reported 1 PR, 1 durable SD, and lack of benefit for 3 patients with glioblastoma multiforme (GBM) (Wisinski et al., 2023; 37053535). Additionally, case studies of trametinib monotherapy for NF1-associated brain tumors have reported PRs for 3 patients with low-grade glioma, 5 patients with astrocytoma, 1 patient with an optic pathway glioma, and 1 patient with a GBM (Manoharan et al., 2020; 32780261, Kondyli et al., 2018; 30097824, Ronsley et al., 2021; 33939292, Lucas et al., 2022; 35945463, Romo et al., 2019; SNO Abstract RARE-54, Awada et al., 2020; 33082744). A minor response was reported for 1 patient with glioma on cobimetinib (Trippett et al., 2022; 35715627). A Phase 1/2 study evaluating the use of cobimetinib for pediatric and young adult patients with relapsed or refractory solid tumors reported an ORR of 9.4% (3/32) among patients with low-grade glioma (Trippett et al., 2022; 35715627). A patient with anaplastic pleomorphic xanthoastrocytoma with leptomeningeal dissemination harboring an ATG7-RAF1 fusion exhibited a complete cytologic response and clinical benefit following treatment with cobimetinib (Touat et al., 2019; DOI: 10.1200/PO.18.00298). &lt;/p&gt;</Rationale>
                  <ApprovedUses />
                  <Effect>Sensitizing</Effect>
                  <Include>true</Include>
                  <IncludeInSummary>true</IncludeInSummary>
                  <ReferenceLinks />
                </Therapy>
                <Therapy>
                  <Name />
                  <GenericName>Selumetinib</GenericName>
                  <FDAApproved>false</FDAApproved>
                  <Rationale>&lt;p&gt;&lt;b&gt;Approved Indications:&lt;/b&gt; Selumetinib is a MEK inhibitor that is FDA approved to treat pediatric patients with neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas (PNs). Please see the drug label for full prescribing information. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Gene Association:&lt;/b&gt; On the basis of clinical evidence in neurofibromatosis type 1 (NF1)-associated neurofibroma (Dombi et al., 2016; 28029918, Schalkwijk et al., 2021; 33903938, Glassberg et al., 2020; ASPHO Abstract 2015, Coyne et al., 2020; ASCO Abstract 3612, McCowage et al., 2018; ASCO Abstract 10504, Mueller et al., 2020; SNO Abstract NFB-17), malignant peripheral nerve sheath tumors (Hitchen et al., 2023; 36743881, Nagabushan et al., 2021; 33580196, Hones et al., 2022; 36192032), and central nervous system tumors including glioma, glioblastoma multiforme (GBM), and astrocytoma (Lucas et al., 2022; 35945463, Fangusaro et al., 2019; 31151904, Manoharan et al., 2020; 32780261, Romo et al., 2019; SNO Abstract RARE-54, Awada et al., 2020; 33082744, Wisinski et al., 2023; 37053535), NF1 inactivation may predict sensitivity to MEK inhibitors. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Supporting Data:&lt;/b&gt; MEK inhibitors have shown efficacy in several studies of low-grade and high-grade central nervous system (CNS) tumors. A Phase 2 study of selumetinib monotherapy for patients with NF1-associated low-grade glioma reported an ORR of 40%, with 10 patients experiencing PRs (Fangusaro et al., 2019; 31151904). An NCI-MATCH subprotocol of trametinib in NF1-mutated solid tumors reported 1 PR, 1 durable SD, and lack of benefit for 3 patients with glioblastoma multiforme (GBM) (Wisinski et al., 2023; 37053535). Additionally, case studies of trametinib monotherapy for NF1-associated brain tumors have reported PRs for 3 patients with low-grade glioma, 5 patients with astrocytoma, 1 patient with an optic pathway glioma, and 1 patient with a GBM (Manoharan et al., 2020; 32780261, Kondyli et al., 2018; 30097824, Ronsley et al., 2021; 33939292, Lucas et al., 2022; 35945463, Romo et al., 2019; SNO Abstract RARE-54, Awada et al., 2020; 33082744). A minor response was reported for 1 patient with glioma on cobimetinib (Trippett et al., 2022; 35715627). Selumetinib has demonstrated clinical activity in low-grade glioma. A Phase 2 study of selumetinib for patients with low-grade glioma (LGG) reported 8/25 PRs for patients with BRAF alterations and 10/25 PRs for those with NF1-associated LGG (Fangusaro et al., 2019; 31151904); a Phase 1 study of selumetinib reported 5/25 PRs for patients with LGG (Banerjee et al., 2017; 28339824). A Phase 2 study of selumetinib for patients with tumors with activating alterations in the MAPK pathway evaluated 8 patients with high-grade glioma (HGG); 2 SDs and no objective responses were observed in this subset (Eckstein et al., 2022; 35363510). &lt;/p&gt;</Rationale>
                  <ApprovedUses />
                  <Effect>Sensitizing</Effect>
                  <Include>true</Include>
                  <IncludeInSummary>true</IncludeInSummary>
                  <ReferenceLinks />
                </Therapy>
                <Therapy>
                  <Name />
                  <GenericName>Trametinib</GenericName>
                  <FDAApproved>false</FDAApproved>
                  <Rationale>&lt;p&gt;&lt;b&gt;Approved Indications:&lt;/b&gt; Trametinib is a MEK inhibitor that is FDA approved as a monotherapy to treat patients with melanoma with BRAF V600E or V600K mutations. Please see the drug label for full prescribing information. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Gene Association:&lt;/b&gt; On the basis of clinical evidence in neurofibromatosis type 1 (NF1)-associated neurofibroma (Dombi et al., 2016; 28029918, Schalkwijk et al., 2021; 33903938, Glassberg et al., 2020; ASPHO Abstract 2015, Coyne et al., 2020; ASCO Abstract 3612, McCowage et al., 2018; ASCO Abstract 10504, Mueller et al., 2020; SNO Abstract NFB-17), malignant peripheral nerve sheath tumors (Hitchen et al., 2023; 36743881, Nagabushan et al., 2021; 33580196, Hones et al., 2022; 36192032), and central nervous system tumors including glioma, glioblastoma multiforme (GBM), and astrocytoma (Lucas et al., 2022; 35945463, Fangusaro et al., 2019; 31151904, Manoharan et al., 2020; 32780261, Romo et al., 2019; SNO Abstract RARE-54, Awada et al., 2020; 33082744, Wisinski et al., 2023; 37053535), NF1 inactivation may predict sensitivity to MEK inhibitors. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Supporting Data:&lt;/b&gt; MEK inhibitors have shown efficacy in several studies of low-grade and high-grade central nervous system (CNS) tumors. A Phase 2 study of selumetinib monotherapy for patients with NF1-associated low-grade glioma reported an ORR of 40%, with 10 patients experiencing PRs (Fangusaro et al., 2019; 31151904). An NCI-MATCH subprotocol of trametinib in NF1-mutated solid tumors reported 1 PR, 1 durable SD, and lack of benefit for 3 patients with glioblastoma multiforme (GBM) (Wisinski et al., 2023; 37053535). Additionally, case studies of trametinib monotherapy for NF1-associated brain tumors have reported PRs for 3 patients with low-grade glioma, 5 patients with astrocytoma, 1 patient with an optic pathway glioma, and 1 patient with a GBM (Manoharan et al., 2020; 32780261, Kondyli et al., 2018; 30097824, Ronsley et al., 2021; 33939292, Lucas et al., 2022; 35945463, Romo et al., 2019; SNO Abstract RARE-54, Awada et al., 2020; 33082744). A minor response was reported for 1 patient with glioma on cobimetinib (Trippett et al., 2022; 35715627). A study of 2 pediatric patients with optic astrocytomas harboring BRAF duplications reported clinical benefit in response to trametinib with reductions in tumor volume (56-66%) and treatment ongoing at 484 and 468 days (Miller et al., 2016; 28009226). A study of 5 patients with KIAA1549-BRAF-fusion-positive pilocytic astrocytoma reported 1 PR and 3 minor responses (Kondyli et al., 2018; 30097824) and, similarly, a patient with low-grade glioma harboring this fusion benefited from trametinib (Wagner et al., 2018; 29369501). A patient with pilocytic astrocytoma harboring an NFIA-RAF1 fusion who had progressed on multiple lines of prior treatment exhibited ongoing SD following treatment with trametinib (Yde et al., 2016; 27810072). Whereas frequent adverse events precluded a recommended Phase 2 dose and schedule for the combination of trametinib and everolimus in a Phase 1b trial for solid tumors (Tolcher et al., 2014; 25344362), a retrospective study for heavily pretreated patients with solid tumors reported tolerable regimens of the combination for 23/31 patients, with 16 patients treated &gt;3 months and evaluable patients achieving a median PFS of 6.5 months (Patterson et al., 2018; AACR Abstract 3891). &lt;/p&gt;</Rationale>
                  <ApprovedUses />
                  <Effect>Sensitizing</Effect>
                  <Include>true</Include>
                  <IncludeInSummary>true</IncludeInSummary>
                  <ReferenceLinks />
                </Therapy>
              </Therapies>
              <ReferenceLinks />
              <ClinicalTrialLinks>
                <ClinicalTrialLink nctId="NCT03239015">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT04803318">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT04985604">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT05125523">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT03905148">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT05580770">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT04720976">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT05036226">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT05159245">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT04817956">
                  <Include>true</Include>
                </ClinicalTrialLink>
              </ClinicalTrialLinks>
            </Alteration>
          </Alterations>
          <ReferenceLinks />
        </Gene>
        <Gene>
          <Name>PDCD1LG2 (PD-L2)</Name>
          <Include>true</Include>
          <Alterations>
            <Alteration>
              <Name>amplification</Name>
              <AlterationProperties>
                <AlterationProperty isEquivocal="false" name="amplification" />
              </AlterationProperties>
              <Interpretation>PDCD1LG2 encodes the programmed cell death 1 ligand 2 (PD-L2), also known as CD273, PD-L2, and B7-DC, which is essential for T-cell proliferation and interferon production. PD-1 signaling, which can be stimulated by PD-L2, results in 'T-cell exhaustion', a temporary inhibition of activation and proliferation that can be reversed on removal of the PD-1 signal (Keir et al., 2008; 18173375, Butte et al., 2007; 17629517). Amplification of PDCD1LG2 and the adjacent locus CD274, encoding PD-L1, has been reported in 29% of primary mediastinal B-cell lymphoma (PMBCL) cases, and PDCD1LG2 copy number gain has been reported to correlate with increased PD-L2 protein expression as determined by immunohistochemistry (Twa et al., 2014; 24497532, Shi et al., 2014; 25025450). PDCD1LG2 amplification was detected in fewer than 1% of caes in the TCGA Brain Lower Grade Glioma and Glioblastoma datasets, while putative homozygous PDCD1LG2 deletion was observed in 0.78% and 1.5% of cases, respectively (cBioPortal, Feb 2023)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). Preclinical data in murine models suggest that anti-PD-1 blockade alone or combined with other therapies may be an effective therapeutic strategy against malignant gliomas (Reardon et al., 2016; 26546453, Zeng et al., 2013; 23462419, Wainwright et al., 2014; 24691018). Analysis of the Chinese Glioma Genome Atlas (CGGA) and TCGA datasets found that PD-L2 expression was upregulated in higher grade and IDH wild-type glioma, and that PD-L2 expression was linked to unfavorable prognosis independent of other variables including age, grade, IDH status, and chromosome 1p/19q status (Wang et al., 2018; 30713802). However, another analysis found that PD-L2 expression was not an independent predictor of prognosis in GBM (Takashima et al., 2018; 29721184). PDCD1LG2 amplification, which is often co-amplified with CD274, may lead to PD-L2 overexpression and predict sensitivity to PD-1, PD-L1, or PD-L2 antibodies. The PD-1 antibodies pembrolizumab and nivolumab and the PD-L1 antibody atezolizumab have elicited significant clinical responses in several cancer types, including melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC) (Robert et al., 2014; 25399552, Weber et al., 2015; 25795410, Larkin et al., 2015; 26027431, Postow et al., 2015; 25891304, Topalian et al., 2014; 24590637, Brahmer et al., 2015; 26028407, Borghaei et al., 2015; 26412456, Rizvi et al., 2015; 25704439, Motzer et al., 2015; 26406148, George et al., 2018; 30524881, Schmid et al., 2016; ASCO Abstract 11506, Fehrenbacher et al., 2016; 26970723), and Hodgkin lymphoma, which harbors frequent PD-L1 and PD-L2 copy number gains (Ansell et al., 2015; ASH Abstract 583, Ansell et al., 2015; 25482239). Additionally, preclinical studies in lymphoma cell lines have demonstrated that JAK2 amplification regulates PD-L2 expression (Green et al., 2010; 20628145, Derenzini et al., 2011; 22829094); therefore, JAK2 inhibitors such as ruxolitinib may also be relevant for patients with PD-L2 amplification.</Interpretation>
              <Include>true</Include>
              <ClinicalTrialNote>PDCD1LG2 (PD-L2) amplification may promote PD-1 signaling and inhibit the anti-tumor immune response. Antibodies that block the interaction of PD-L2 and PD-1 may therefore be beneficial to release the anti-tumor immune response. Furthermore, JAK2 inhibitors may be relevant, because they may reduce PD-L2 expression.</ClinicalTrialNote>
              <Therapies>
                <Therapy>
                  <Name />
                  <GenericName>Retifanlimab</GenericName>
                  <FDAApproved>false</FDAApproved>
                  <Rationale>&lt;p&gt;&lt;b&gt;Approved Indications:&lt;/b&gt; Retifanlimab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, reducing inhibition of the antitumor response. It is FDA approved to treat patients with Merkel cell carcinoma. Please see the drug label for full prescribing information. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Gene Association:&lt;/b&gt; Activation of PDCD1LG2 may lead to overexpression of PD-L2 and may confer sensitivity to PD-1 inhibitors such as retifanlimab. CD274 alterations, such as amplification or rearrangement, may lead to overexpression of PD-L1 and predict sensitivity to PD-L1-blocking antibodies such as retifanlimab based on clinical evidence in multiple solid tumor types (Oaknin et al., 2020; 33001143, Subramanian et al., 2020; ESMO Abstract 1399P, Andre et al., 2021; ASCO GI Abstract 9, Gabrail et al., 2019; ASCO Abstract 2560). &lt;/p&gt; &lt;p&gt;&lt;b&gt;Supporting Data:&lt;/b&gt; For patients with recurrent glioblastoma, a Phase 2 study of retifanlimab plus bevacizumab and hypofractionated radiotherapy showed an ORR of 58% (14/24), median PFS of 7.0 months, and median OS of 12.2 months (Butt et al., 2022; SNO Abstract CTIM-10). In the same setting, another Phase 2 study of retifanlimab plus the GITR agonist INCAGN01876 and fractionated stereotactic radiotherapy reported no responses, a DCR of 56% (9/16), median PFS of 3.9 months, and median OS of 9.8 months (Bagley et al., 2022; SNO Abstract CTIM-35). &lt;/p&gt;</Rationale>
                  <ApprovedUses />
                  <Effect>Sensitizing</Effect>
                  <Include>true</Include>
                  <IncludeInSummary>true</IncludeInSummary>
                  <ReferenceLinks />
                </Therapy>
                <Therapy>
                  <Name />
                  <GenericName>Durvalumab</GenericName>
                  <FDAApproved>false</FDAApproved>
                  <Rationale>&lt;p&gt;&lt;b&gt;Approved Indications:&lt;/b&gt; Durvalumab is a monoclonal antibody that binds to PD-L1 and blocks its interaction with PD-1 to enhance antitumor immune responses. It is FDA approved to treat patients with non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and biliary tract cancer. Please see the drug label for full prescribing information. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Gene Association:&lt;/b&gt; CD274 alterations, such as amplification or rearrangement, may lead to overexpression of PD-L1 and predict sensitivity to PD-L1-blocking antibodies such as durvalumab based on clinical evidence in multiple solid tumor types (Schmid et al., 2016; ASCO Abstract 11506, Disis et al., 2016; ASCO Abstract 5533, Dirix et al., 2016; SABCS Abstract S1-04, Verschraegen et al., 2016; ASCO Abstract 9036, Gulley et al., 2015; ECC Abstract 3090, Powles et al., 2017; ASCO Genitourinary Abstract 286, Segal et al., 2015; ASCO Abstract 3011, Rebelatto et al., 2015; ASCO Abstract 8033, Bais et al., 2017; AACR Abstract 3720/5, Garassino et al., 2016; IASLC Abstract PLO4a.03)(Fehrenbacher et al., 2016; 26970723, Herbst et al., 2015; 25680375, Massard et al., 2016; 27269937). Amplification of PDCD1LG2, which is often co-amplified with CD274, may lead to PD-L2 overexpression and predict sensitivity to PD-L1-blocking antibodies such as durvalumab. Although durvalumab does not block the interaction between PD-L2 and PD-1, clinical evidence in multiple solid tumor types suggests that PD-L2 expression may correlate with improved OS and response to the similar PD-L1-blocking antibody atezolizumab (Schmid et al., 2016; ASCO Abstract 11506, Herbst et al., 2015; 25680375, Fehrenbacher et al., 2016; 26970723). &lt;/p&gt; &lt;p&gt;&lt;b&gt;Supporting Data:&lt;/b&gt; A Phase 2 study of durvalumab combined with standard radiotherapy followed by durvalumab monotherapy for patients with newly diagnosed unmethylated MGMT glioblastoma after resection reported a 12-month OS of 60.0% (24/40) and median OS of 15.1 months (Reardon et al., 2019; ASCO Abstract 2032). A Phase 2 study of durvalumab and 10 or 3 mg/kg bevacizumab (cohorts B2 and B3, respectively) for the treatment of bevacizumab-naive recurrent glioblastoma reported 9.1% (3/33) PRs in both cohorts and a 6-month PFS rate of 15.2% and 21.1%, respectively (Reardon et al., 2018; SNO Abstract ATIM-38). A Phase 2 study of durvalumab combined with bevacizumab for the treatment of bevacizumab-refractory recurrent glioblastoma reported 50.0% (11/22) of patients had PFS greater than 8 weeks and 36.4% (8/22) of patients had OS greater than 22 weeks (Reardon et al., 2017; SNO Abstract ATIM-12). &lt;/p&gt;</Rationale>
                  <ApprovedUses />
                  <Effect>Sensitizing</Effect>
                  <Include>true</Include>
                  <IncludeInSummary>true</IncludeInSummary>
                  <ReferenceLinks />
                </Therapy>
                <Therapy>
                  <Name />
                  <GenericName>Cemiplimab</GenericName>
                  <FDAApproved>false</FDAApproved>
                  <Rationale>&lt;p&gt;&lt;b&gt;Approved Indications:&lt;/b&gt; Cemiplimab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with the ligands PD-L1 and PD-L2 to enhance antitumor immune responses. It is FDA approved to treat patients with non-small cell lung cancer (NSCLC), cutaneous squamous cell carcinoma, or basal cell carcinoma. Please see the drug label for full prescribing information. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Gene Association:&lt;/b&gt; Amplification of CD274 or PDCD1LG2 may lead to overexpression of PD-1 ligand(s). In multiple cancer types, PD-L1 expression correlated positively with PD-1 (on lymphocytes) and PD-L2 expression as well as improved clinical benefit in response to anti-PD-1 immunotherapies (Kefford et al., 2014; ASCO Abstract 3005, Garon et al., 2015; 25891174, Herbst et al., 2015; 26712084, Taube et al., 2014; 24714771, Bellone et al., 2015; 29351920, Topalian et al., 2012; 22658127, Ansell et al., 2015; ASH Abstract 583, Ansell et al., 2015; 25482239) and may predict sensitivity to cemiplimab. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Supporting Data:&lt;/b&gt; A Phase 1/2 trial of cemiplimab in combination with the investigational immunotherapeutic agents INO-5401 and INO-9012 reported a 12-month OS of 84% for patients with glioblastoma multiforme (GBM) and unmethylated-MGMT status (Reardon et al., 2020; ASCO Abstract 2514). In the neoadjuvant setting, cemiplimab was also associated with clinical benefit for 1 patient with high-grade glioma following a third recurrence and subsequent resection in a case report (McCord et al., 2021; 34250480). Cemiplimab has been studied primarily in advanced cutaneous squamous cell carcinoma (CSCC), where it elicited a combined ORR of 48% (41/85) in Phase 1 and 2 studies (Migden et al., 2018; 29863979). A Phase 2 trial of cemiplimab in patients with basal cell carcinoma (BCC) reported ORRs of 31% (5 CRs and 21 PRs) in patients with locally advanced BCC and 21% (6 PRs) in patients with metastatic BCC (Stratigos et al., 2020; EMSO Abstract LBA47, Lewis et al. 2020; doi: 10.1136/jitc-2020-SITC2020.0428). The Phase 3 EMPOWER-Lung 1 trial for advanced non-small cell lung cancer (NSCLC) with PD-L1 expression ≥50% reported that cemiplimab is associated with improved PFS (8.2 vs. 5.7 months), OS (not reached vs. 14.2 months), and ORR (37% vs. 21%) compared with chemotherapy (Sezer et al., 2020; ESMO Abstract LBA52). &lt;/p&gt;</Rationale>
                  <ApprovedUses />
                  <Effect>Sensitizing</Effect>
                  <Include>true</Include>
                  <IncludeInSummary>true</IncludeInSummary>
                  <ReferenceLinks />
                </Therapy>
                <Therapy>
                  <Name />
                  <GenericName>Pembrolizumab</GenericName>
                  <FDAApproved>true</FDAApproved>
                  <Rationale>&lt;p&gt;&lt;b&gt;Approved Indications:&lt;/b&gt; Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with the ligands PD-L1 and PD-L2 to enhance antitumor immune responses. It is FDA approved for patients with tumor mutational burden-high (≥10 Muts/Mb), microsatellite instability-high (MSI-H), or MMR-deficient (dMMR) solid tumors; as monotherapy for PD-L1-positive head and neck squamous cell cancer (HNSCC), cervical cancer, or esophageal cancer; and in combination with chemotherapy for PD-L1-positive triple-negative breast cancer (TNBC) or cervical cancer. It is also approved in various treatment settings as monotherapy for patients with non-small cell lung cancer (NSCLC), melanoma, HNSCC, urothelial carcinoma, hepatocellular carcinoma, Merkel cell carcinoma, cutaneous squamous cell carcinoma, MSI-H or dMMR endometrial carcinoma, classical Hodgkin lymphoma, or primary mediastinal large B-cell lymphoma; and in combination with chemotherapy or targeted therapy for NSCLC, HNSCC, esophageal or gastroesophageal junction cancer, renal cell carcinoma, TNBC, urothelial carcinoma, or endometrial carcinoma that is not MSI-H or dMMR. Please see the drug label for full prescribing information. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Gene Association:&lt;/b&gt; Amplification of CD274 or PDCD1LG2 may lead to overexpression of PD-1 ligand(s) and may predict sensitivity to pembrolizumab. Treatment with pembrolizumab has resulted in a lasting CR in a patient with CD274-amplified DLBCL (Godfrey et al., 2019; 30910787) and in a lasting PR in a patient with CD274-amplified cancer of unknown primary (Gröschel et al., 2016; 27900363). PD-L1 expression is associated with significantly prolonged median OS for patients with EGFR/ALK wildtype advanced NSCLC treated with pembrolizumab compared with chemotherapy (Mok et al 2019; 30955977, Reck et al., 2019; 30620668, Herbst et al., 2016; 26712084). One trial in patients with melanoma observed an improved objective response rate (51% vs. 6%) and PFS (12 vs. 3 months) for PD-L1 positive compared to PD-L1 negative tumors (Kefford et al., 2014; ASCO Abstract 3005). Furthermore, PD-L1 expression correlated positively with expression of PD-1 (on lymphocytes) and PD-L2, as well as with objective response to the anti-PD-1 antibody nivolumab in various advanced solid tumors (Taube et al., 2014; 24714771). &lt;/p&gt; &lt;p&gt;&lt;b&gt;Supporting Data:&lt;/b&gt; A Phase 2 study of patients with bevacizumab-naïve, recurrent glioblastoma (GBM) reported that single-agent pembrolizumab had limited activity; similar median PFS (1.4 vs. 4.1 months) and OS (10.3 vs. 8.8 months) were reported for pembrolizumab monotherapy and pembrolizumab combined with bevacizumab, respectively (Reardon et al., 2018; ASCO Abstract 2006). Similar PFS (2.8 months) and OS (14.4 months) were reported for bevacizumab-naïve, recurrent PD-L1-positive GBM (≥1% in tumor or immune cells) treated with pembrolizumab monotherapy in the Phase 1b KEYNOTE-028 study (Reardon et al., 2016; SNO Abstract ATIM-35). Administration of pembrolizumab both before and after surgery in the treatment of recurrent GBM achieved lasting response (&gt;34 months) for 13.3% (2/15) of patients in a single-arm study (De Groot et al., 2018; ASCO Abstract 2008). Combination of pembrolizumab with bevacizumab and stereotactic radiation in 23 adults with recurrent GBM or anaplastic astrocytoma elicited durable responses (CR or PR ≥6 months) in 53% of patients (Sahebjam et al., 2017; SNO Abstract ATIM-18). &lt;/p&gt;</Rationale>
                  <ApprovedUses />
                  <Effect>Sensitizing</Effect>
                  <Include>true</Include>
                  <IncludeInSummary>true</IncludeInSummary>
                  <ReferenceLinks />
                </Therapy>
                <Therapy>
                  <Name />
                  <GenericName>Nivolumab</GenericName>
                  <FDAApproved>false</FDAApproved>
                  <Rationale>&lt;p&gt;&lt;b&gt;Approved Indications:&lt;/b&gt; Nivolumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, reducing inhibition of the antitumor immune response. It is FDA approved as a monotherapy in various treatment settings for patients with melanoma, renal cell carcinoma (RCC), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), urothelial carcinoma, colorectal cancer (CRC), classical Hodgkin lymphoma (cHL), gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma or squamous cell carcinoma (ESCC). It is also approved in combination with chemotherapy to treat ESCC, in combination with cabozantinib to treat RCC, and in combination with relatlimab to treat melanoma. Please see the drug label for full prescribing information. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Gene Association:&lt;/b&gt; Amplification of CD274 or PDCD1LG2 may lead to overexpression of PD-1 ligand(s) and may predict sensitivity to nivolumab. In various advanced solid tumors, including melanoma, lung, kidney, prostate, and colorectal cancer, PD-L1 expression correlated positively with PD-1 (on lymphocytes) and PD-L2 expression as well as with objective response to nivolumab (Taube et al., 2014; 24714771, Topalian et al., 2012; 22658127). &lt;/p&gt; &lt;p&gt;&lt;b&gt;Supporting Data:&lt;/b&gt; The CheckMate 143 Phase 3 trial comparing nivolumab monotherapy to bevacizumab in recurrent glioblastoma (GBM) reported similar PFS (1.5 vs. 3.5 months) and median OS (9.8 vs. 10.0 months), although nivolumab elicited a numerically longer duration of response (11.1 vs. 5.3 months) (Reardon et al., 2020; 32437507). Exploratory CheckMate-143 cohorts showed combination of nivolumab and radiotherapy, with or without temozolomide, to be well tolerated (Lim et al., 2017; ESMO Abstract 325O); these regimens are being further evaluated in the CheckMate-548 (NCT02667587) study in newly diagnosed GBM. Retrospective studies in recurrent GBM or high-grade glioma reported stable disease rates of 56% (9/16) to 72% (36/50) for nivolumab alone or in combination with bevacizumab, with Grade 3/4 treatment-related AEs in 8% (4/50) to 13% (2/16) of patients (Chamberlain and Kim, 2017; 28500559, Mantica et al., 2018; 29779086). Biallelic mismatch repair deficiency (bMMRD)-associated GBMs harbor extraordinarily high mutational loads (Shlien et al., 2015; 25642631, Bouffet et al., 2016; 27001570), and three pediatric patients with bMMRD-associated GBM achieved clinically and radiologically significant responses to nivolumab monotherapy (Bouffet et al., 2016; 27001570, AlHarbi et al., 2018; 30104292). An adult with previously treated GBM experienced tumor shrinkage and disease stabilization for 2 years after pseudoprogression on nivolumab (Roth et al., 2017; 28039369). In a Phase 1 study, three patients with progressive GBM benefited from regimens combining nivolumab with surgery and the VEGFR2-targeting vaccine VXM01 (Wick et al., 2018; ASCO Abstract 2017). &lt;/p&gt;</Rationale>
                  <ApprovedUses />
                  <Effect>Sensitizing</Effect>
                  <Include>true</Include>
                  <IncludeInSummary>true</IncludeInSummary>
                  <ReferenceLinks />
                </Therapy>
                <Therapy>
                  <Name />
                  <GenericName>Dostarlimab</GenericName>
                  <FDAApproved>true</FDAApproved>
                  <Rationale>&lt;p&gt;&lt;b&gt;Approved Indications:&lt;/b&gt; Dostarlimab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, reducing inhibition of the antitumor response. It is FDA approved to treat patients with mismatch repair deficient recurrent or advanced endometrial cancer or solid tumors. Please see the drug label for full prescribing information. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Gene Association:&lt;/b&gt; Activation of PDCD1LG2 may lead to overexpression of PD-L2 and may confer sensitivity to PD-1 inhibitors such as dostarlimab. CD274 alterations, such as amplification or rearrangement, may lead to overexpression of PD-L1 and predict sensitivity to PD-L1-blocking antibodies such as dostarlimab based on clinical evidence in multiple solid tumor types (Oaknin et al., 2020; 33001143, Subramanian et al., 2020; ESMO Abstract 1399P, Andre et al., 2021; ASCO GI Abstract 9, Gabrail et al., 2019; ASCO Abstract 2560). &lt;/p&gt; &lt;p&gt;&lt;b&gt;Supporting Data:&lt;/b&gt; Clinical data on the efficacy of dostarlimab for the treatment of CNS tumors are limited (PubMed, Jan 2023). Dostarlimab has been studied primarily in recurrent and advanced mismatch repair-deficient (dMMR) endometrial and non-endometrial cancers (Andre et al., 2021; ASCO GI Abstract 9, Oaknin et al., 2020; 33001143, Berton et al., 2021; ASCO Abstract 2564). In the Phase 1 GARNET trial, single-agent dostarlimab elicited an ORR of 39% (41/106) and an immune-related ORR of 46% (50/110) for patients with non-endometrial dMMR solid tumors (Andre et al., 2021; ASCO GI Abstract 9, Andre et al., 2021; ESMO GI Abstract SO-9). &lt;/p&gt;</Rationale>
                  <ApprovedUses />
                  <Effect>Sensitizing</Effect>
                  <Include>true</Include>
                  <IncludeInSummary>true</IncludeInSummary>
                  <ReferenceLinks />
                </Therapy>
                <Therapy>
                  <Name />
                  <GenericName>Atezolizumab</GenericName>
                  <FDAApproved>false</FDAApproved>
                  <Rationale>&lt;p&gt;&lt;b&gt;Approved Indications:&lt;/b&gt; Atezolizumab is a monoclonal antibody that binds to PD-L1 and blocks its interaction with PD-1 to enhance antitumor immune responses. It is FDA approved to treat patients with non-small cell lung cancer (NSCLC) as well as adult and pediatric patients 2 years and older with alveolar soft part sarcoma, depending on treatment setting. Atezolizumab is also approved in combination with other therapies to treat patients with non-squamous NSCLC lacking EGFR or ALK alterations, small cell lung cancer, hepatocellular carcinoma, and BRAF V600-positive melanoma. Please see the drug label for full prescribing information. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Gene Association:&lt;/b&gt; CD274 alterations, such as amplification or rearrangements, that lead to overexpression of PD-L1 may predict sensitivity to atezolizumab based on clinical evidence in multiple solid tumor types (Schmid et al., 2016; ASCO Abstract 11506)(Fehrenbacher et al., 2016; 26970723, Herbst et al., 2015; 25680375). Amplification of PDCD1LG2, which is often co-amplified with CD274, may lead to PD-L2 overexpression and predict sensitivity to anti-PD-L1 inhibitors such as atezolizumab. Although atezolizumab does not block the interaction between PD-L2 and PD-1, clinical evidence in multiple solid tumor types suggests that PD-L2 expression may correlate with improved OS and response to atezolizumab (Schmid et al., 2016; ASCO Abstract 11506, Herbst et al., 2015; 25680375, Fehrenbacher et al., 2016; 26970723). &lt;/p&gt; &lt;p&gt;&lt;b&gt;Supporting Data:&lt;/b&gt; In a Phase 1a of atezolizumab for patients with glioblastoma (GBM) who had failed prior radiotherapy and/or temazolomide, an objective response rate (ORR) of 6% (1/16) was observed, with 1 patient achieving a partial response (PR) for 16 months and 3 others achieving stable disease (SD); of these 4 patients, all were microsatellite stable, 3 (including the patient with a PR) harbored IDH1 R132H mutations, and 2 experienced an overall survival (OS) of &gt;16 months (Lukas et al., 2018; 30073642). A patient with POLE L424V-mutated GBM enrolled in this study achieved an OS of ~18 months (Lukas et al., 2018; 30073642). In a retrospective analysis of 17 solid tumor types (comprised of 47% NSCLC, 40% mUC, and 13% encompassing 15 other solid tumors, including GBM), a TMB of ≥16 muts/Mb associated with an improved ORR and duration of response to atezolizumab compared with chemotherapy alone (Legrand et al., 2018; ASCO Abstract 12000). Atezolizumab has been studied primarily for treating non-small cell lung cancer (NSCLC) (Smith et al., 2016; ASCO Abstract 9028, Mazieres et al., 2016; ASCO Abstract 9032, Besse et al., 2015; ECC Abstract 16LBA, Spigel et al., 2015; ASCO Abstract 8028, Fehrenbacher et al., 2016; 26970723, Herbst et al., 2014; 25428504) and urothelial carcinoma (Balar et al., 2016; ASCO Abstract LBA4500, Dreicer et al., 2016; ASCO Abstract 4515) (Rosenberg et al., 2016; 26952546, Powles et al., 2014; 25428503). A study of atezolizumab as monotherapy for patients with advanced solid tumors reported a median PFS of 18 weeks and an ORR of 21%, including confirmed responses in 26% (11/43) of melanomas, 13% (7/56) of renal cell carcinomas (RCC) and 17% (1/6) of colorectal cancers (CRCs)(Herbst et al., 2014; 25428504). As a single-agent therapy in genomically unselected young patients (&lt;30 years old) with relapsed or refractory cancers, atezolizumab elicited an ORR of 1.5% (1/67) for patients with solid tumors, with similar safety and pharmacokinetics as seen in adults (Geoerger et al., 2020; 31780255). A Phase 1a study of atezolizumab reported an ORR of 15% (9/62), a median PFS of 5.6 months, and a median OS of 28.9 months for patients with clear cell renal cell carcinoma (ccRCC) (McDermott et al., 2016; 26755520). A Phase 1b study evaluated atezolizumab combined with nab-paclitaxel for patients with previously treated metastatic triple-negative breast cancer (mTNBC) and reported confirmed objective responses for 42% (10/24) of patients; no dose-limiting toxicities were observed (Adams et al., 2016; ASCO Abstract 1009). A Phase 1b study that evaluated atezolizumab in combination with the MEK inhibitor cobimetinib for advanced solid tumors reported an ORR of 8.3% (7/84) for patients with CRC, 41% (9/22) for patients with melanoma, 18% (5/28) for patients with NSCLC, and 19% (3/16) for patients with other tumors (ovarian cancer, clear-cell sarcoma, and RCC); there was no association between BRAF or KRAS mutation status and response rate in any disease setting, and no dose-limiting toxicities were encountered (Hellmann et al., 2019; 30918950, Bendell et al., 2016; ASCO Abstract 3502). &lt;/p&gt;</Rationale>
                  <ApprovedUses />
                  <Effect>Sensitizing</Effect>
                  <Include>true</Include>
                  <IncludeInSummary>true</IncludeInSummary>
                  <ReferenceLinks />
                </Therapy>
                <Therapy>
                  <Name />
                  <GenericName>Avelumab</GenericName>
                  <FDAApproved>false</FDAApproved>
                  <Rationale>&lt;p&gt;&lt;b&gt;Approved Indications:&lt;/b&gt; Avelumab is a monoclonal antibody that binds to PD-L1 and blocks its interaction with PD-1 in order to enhance antitumor immune responses. It is FDA approved to treat patients 12 years and older with Merkel cell carcinoma, or for urothelial carcinoma in various treatment settings. The combination of avelumab and axitinib is FDA approved for patients with renal cell carcinoma (RCC). Please see the drug label for full prescribing information. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Gene Association:&lt;/b&gt; CD274 alterations, such as amplification or rearrangement, may lead to overexpression of PD-L1 and predict sensitivity to PD-L1-blocking antibodies such as avelumab based on clinical evidence in multiple solid tumor types (Schmid et al., 2016; ASCO Abstract 11506, Disis et al., 2016; ASCO Abstract 5533, Dirix et al., 2016; SABCS Abstract S1-04, Verschraegen et al., 2016; ASCO Abstract 9036, Gulley et al., 2015; ECC Abstract 3090)(Fehrenbacher et al., 2016; 26970723, Herbst et al., 2015; 25680375). Amplification of PDCD1LG2, which is often co-amplified with CD274, may lead to PD-L2 overexpression and predict sensitivity to PD-L1-blocking antibodies such as avelumab. Although avelumab does not block the interaction between PD-L2 and PD-1, clinical evidence in multiple solid tumor types suggests that PD-L2 expression may correlate with improved OS and response to the similar PD-L1-blocking antibody atezolizumab (Schmid et al., 2016; ASCO Abstract 11506, Herbst et al., 2015; 25680375, Fehrenbacher et al., 2016; 26970723). &lt;/p&gt; &lt;p&gt;&lt;b&gt;Supporting Data:&lt;/b&gt; A Phase 2 open-label study of avelumab monotherapy for the treatment of newly diagnosed glioblastoma after treatment with combined radiotherapy and temozolomide reported an ORR (iRANO) of 50.0% (2 CR, 1 PR, 1 SD) and median PFS of 11.9 months (Jacques et al., 2019; ASCO Abstract e13751). A Phase 2 study of avelumab with hypofractionated radiotherapy for the treatment of IDH-mutated glioblastoma after radiotherapy and temozolomide reported 1 out of 6 SD as best response, median PFS of 4.2 months, and median OS of 10.1 months (Kurz et al., 2019; SNO Abstract ATIM-37). A Phase 2 open-label study of axitinib combined with avelumab for the treatment of recurrent glioblastoma following surgery, radiotherapy, and temozolomide treatment reported an ORR (iRANO) of 41%, 6-month PFS of 18%, and median OS of 26 weeks (Neyns et al., 2019; ASCO Abstract 2034). &lt;/p&gt;</Rationale>
                  <ApprovedUses />
                  <Effect>Sensitizing</Effect>
                  <Include>true</Include>
                  <IncludeInSummary>true</IncludeInSummary>
                  <ReferenceLinks />
                </Therapy>
              </Therapies>
              <ReferenceLinks />
              <ClinicalTrialLinks>
                <ClinicalTrialLink nctId="NCT04237649">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT04047862">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT05166577">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT03530397">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT03821935">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT04215978">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT05024214">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT03744468">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT04892498">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT05142423">
                  <Include>true</Include>
                </ClinicalTrialLink>
              </ClinicalTrialLinks>
            </Alteration>
          </Alterations>
          <ReferenceLinks />
        </Gene>
        <Gene>
          <Name>H3-3A (H3F3A)</Name>
          <Include>true</Include>
          <Alterations>
            <Alteration>
              <Name>K28M</Name>
              <AlterationProperties>
                <AlterationProperty dnaFraction="34.3" isEquivocal="false" name="K28M" />
              </AlterationProperties>
              <Interpretation>H3F3A encodes the histone 3 variant H3.3. Histones form part of the nucleosome complex around which DNA is coiled in the cell. H3F3A mutations affecting different hotspot residues, such as G35 (commonly referred to as G34 in the literature) and K28 (commonly known as K27), form different subgroups based on methylation and gene expression differences, the region of the brain affected, and clinical parameters (Sturm et al., 2012; 23079654). Recurrent mutations in the histone tail of H3F3A, at sites involved in critical post-translational modifications, have been reported at high frequency in pediatric and young adult brain tumors, including diffuse midline gliomas (Solomon et al., 2016; 26517431), diffuse hemispheric glioma (Fontebasso et al., 2013; 23417712), glioblastomas (Pandit et al., 2016; ISPNO Abstract HG-58)(Schwartzentruber et al., 2012; 22286061, Venneti et al., 2014; 25200322), aggressive pediatric gliomas (Wu et al., 2012; 22286216), pilocytic astrocytomas (Hochart et al., 2015; 25909089), gangliogliomas (Joyon et al., 2016; 27219822), glial and glioneuronal tumors (Nguyen et al., 2015; 25389051), as well as in low-grade gliomas undergoing transformation and secondary high-grade gliomas (Mistry et al., 2015; 25667294). These mutations were commonly found concurrently with mutations in TP53 or in ATRX and DAXX, which form a complex required for H3.3 recruitment to DNA, and were mutually exclusive with IDH1 mutations, which indirectly affect methylation of critical H3.3 residues (Schwartzentruber et al., 2012; 22286061). H3F3A K28M (also known as K27M) is a poor prognostic marker in glioma (NCCN CNS Cancers Guidelines, v2.2022). H3F3A G35 mutations are associated with disease onset during adolescence, whereas K28 mutations affect younger children and predict poorer IOS (Sturm et al., 2012; 23079654, Venneti et al., 2014; 25200322). H3F3A K28M mutation has also been identified in 58% of adult midline gliomas, and is associated with shorter OS for patients with brainstem gliomas but not for patients with thalamic gliomas (Feng et al., 2015; 26297251). Mutations of H3F3A or H3F3B, the other gene encoding histone H3.3, have also been detected in giant cell tumor of bone and chondroblastoma, with low mutation frequencies in other tumors of cartilage and bone (Behjati et al., 2013; 24162739, Kervarrec et al., 2017; 28059095, Righi et al., 2017; 28899740). H3F3B K37M (commonly known as K36M) has been identified in head and neck squamous cell carcinoma, specifically in tumors of the oral cavity (Papillon-Cavanagh et al., 2017; 28067913). Overexpression of H3F3A is associated with poor survival in lung adenocarcinomas, and is thought to promote cancer cell invasion (Park et al., 2016; 27694942). Prospective data from pooled clinical studies and preclinical evidence suggest that H3F3A K28M mutation predicts benefit from the investigational selective dopamine receptor D2 (DRD2) antagonist ONC201 (Chi et al., 2018; SNO abstract ACTR-34, Gardner et al., 2018; SNO abstract PDCT-06, Arrillaga-Romany et al., 2017; 29108308, Prabhu et al., 2018; 30559168), which is supported by increased expression of the ONC201 target DRD2 in H3F3A K28M-mutant versus wild-type gliomas (Chi et al, 2017; SNO abstract EXTH-42, Prabhu et al., 2018; 30559168). Among adult patients with recurrent H3F3A K28M-mutant gliomas, ONC201 achieved a DCR of 64% (7/11) and a 6-month PFS rate of 36% (5/14), with 3 patients experiencing complete and durable regressions of thalamic lesions (Chi et al., 2018; SNO abstract ACTR-34). Data from pooled ONC201 monotherapy trials showed that 31% (9/29) of patients with recurrent H3F3A K28M-mutated glioma remain progression free at 6.5 months median follow-up (Arrillaga et al., 2019; ASCO abstract 3005). Although other H3F3A mutations have been reported (Johnson et al., 2017; 28912153), it is unclear whether these therapeutic strategies would be relevant in gliomas with H3F3A mutations other than K28M. Patients with pediatric H3 K27-altered diffuse midline glioma may benefit from radiotherapy, either as a single modality or combined with alkylating agents (NCCN Pediatric Central Nervous Systems Cancers, v2.2023). H3F3A K27M mutation is characteristic of diffuse midline glioma, H3 K27M-altered (NCCN CNS Cancers Guidelines, v2.2022, NCCN Pediatric CNS Cancers Guidelines, v2.2023)(Louis et al., 2021; 34185076, Pfister et al., 2022; 34921008).</Interpretation>
              <Include>true</Include>
              <ClinicalTrialNote />
              <Therapies />
              <ReferenceLinks />
              <ClinicalTrialLinks />
            </Alteration>
          </Alterations>
          <ReferenceLinks />
        </Gene>
        <Gene>
          <Name>JAK2</Name>
          <Include>true</Include>
          <Alterations>
            <Alteration>
              <Name>amplification</Name>
              <AlterationProperties>
                <AlterationProperty isEquivocal="false" name="amplification" />
              </AlterationProperties>
              <Interpretation>JAK2 encodes Janus kinase 2, a tyrosine kinase that regulates signals triggered by cytokines and growth factors (Jatiani et al., 2010; 21442038). JAK2 is often mutated in hematopoietic and lymphoid cancers. Cell lines and primary lymphoid cancer cells from a small number of patients with JAK2 amplification exhibit overabundance of JAK2 mRNA, protein, and phosphorylated JAK2 targets and respond to JAK2 inhibitors such as ruxolitinib similarly to JAK2-rearranged (activated) cell lines and primary blood cells from patients (Green et al., 2010; 20628145, Chase et al., 2013; 22875628). JAK2 alterations are very rare in glioma and glioblastoma (GBM); in the TCGA datasets JAK2 mutations were reported in 1% of cases analyzed (cBioPortal, Jun 2022)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). Several preclinical studies have demonstrated activity of JAK2/STAT3 inhibitors against GBM cells and mouse models, particularly in EGFR-mutant GBM (Mukthavaramet al., 2015; 26283544, Baskin et al., 2014; 25162558, Zheng et al., 2014; 24861878, He et al., 2013; 23838182, Stechishin et al., 2013; 23262510, Sai et al., 2012; 22249692). Published data investigating the prognostic implications of JAK2 alterations in glioma and GBM are limited (PubMed, Jun 2022). While JAK2 inhibitors have shown clinical benefit in hematological malignancies, clinical utility in solid tumors has not been demonstrated.</Interpretation>
              <Include>true</Include>
              <ClinicalTrialNote />
              <Therapies />
              <ReferenceLinks />
              <ClinicalTrialLinks />
            </Alteration>
          </Alterations>
          <ReferenceLinks />
        </Gene>
        <Gene>
          <Name>Microsatellite status</Name>
          <Include>true</Include>
          <Alterations>
            <Alteration>
              <Name>MS-Stable</Name>
              <AlterationProperties>
                <AlterationProperty isEquivocal="false" name="MS-Stable" />
              </AlterationProperties>
              <Interpretation>Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). This sample is microsatellite-stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers (Boland et al., 1998; 9823339, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins (Kocarnik et al., 2015; 26337942, Bairwa et al., 2014; 24623249, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). Low-level MSI has been reported in 5-9% of glioblastoma (GBM) samples (Martinez et al., 2004; 15331927, Martinez et al., 2005; 15672285, Martinez et al., 2007; 17498554). A large-scale study did not find high-level microsatellite instability (MSI-H) in any of 129 GBM samples (Martinez et al., 2004; 15331927), although a small-scale study reported MSI-H in 4 of 15 pediatric GBMs and 1 of 12 adult GBMs (Szybka et al., 2003; 12908754). The frequency of MSI has been reported to be increased in relapsed compared to primary GBM (Martinez et al., 2004; 15331927), in GBMs with a previous lower grade astrocytoma (Martinez et al., 2005; 15672285), and in giant cell GBM compared to classic GBM (Martinez et al., 2007; 17498554). On the basis of clinical evidence, MSS tumors are significantly less likely than MSI-H tumors to respond to anti-PD-1 immune checkpoint inhibitors (Gatalica et al., 2014; 25392179, Kroemer et al., 2015; 26140250, Lal et al., 2015; 25949894), including approved therapies nivolumab and pembrolizumab (Overman et al., 2016; ASCO Abstract 3501, Le et al., 2015; 26028255). In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI-H and experienced a significantly higher ORR compared with non-MSI-H cases (70% vs. 12%, p=0.001) (Ayers et al., 2016; ASCO-SITC Abstract P60).</Interpretation>
              <Include>true</Include>
              <ClinicalTrialNote />
              <Therapies />
              <ReferenceLinks />
              <ClinicalTrialLinks />
            </Alteration>
          </Alterations>
          <ReferenceLinks />
        </Gene>
        <Gene>
          <Name>TP53</Name>
          <Include>true</Include>
          <Alterations>
            <Alteration>
              <Name>M1R</Name>
              <AlterationProperties>
                <AlterationProperty dnaFraction="61.91" isEquivocal="false" name="M1R" />
              </AlterationProperties>
              <Interpretation>Functional loss of the tumor suppressor p53, which is encoded by the TP53 gene, is common in aggressive advanced cancers (Brown et al., 2009; 19935675). Although alterations such as seen here have not been fully characterized and are of unknown functional significance, similar alterations have been previously reported in the context of cancer, which may indicate biological relevance. In the TCGA dataset, TP53 alterations have been reported in 35% of glioblastomas (GBMs), with a high incidence in pediatric and secondary GBMs and a low incidence in primary GBMs (Cancer Genome Atlas Research Network., 2008; 18772890, Jha et al., 2011; 22089350). One study detected TP53 alterations in 31% (73/232) of IDH-wildtype GBM samples analyzed, with most of the events being mutations (Yan et al. 2020; DOI:10.1200/PO.19.00385). TP53 mutations have been reported in 18-40% of astrocytoma samples, and preferentially in anaplastic astrocytoma; one study reported TP53 loss of function and partially/fully functional mutations in 15% and 25% of anaplastic astrocytomas, respectively (Uno et al., 2005; 15914282, Uno et al., 2006; 16711514, Lass et al., 2012; 22844452, Faria et al., 2012; 23009112, Milinkovic et al., 2013; 24358143, Galatro et al., 2013; 23613880). Some studies suggest that the presence of a TP53 mutation is correlated with a favorable prognosis in patients with glioblastoma (GBM) (Schmidt et al., 2002; 11939587). One study reported that TP53 alterations were associated with poorer OS (12.9 months altered vs. 19.7 months wildtype, HR=1.58, p=0.0054) in IDH-wildtype GBM (Yan et al. 2020; DOI:10.1200/PO.19.00385). Mutation of TP53 is thought to be an early step in the tumorigenesis of astrocytomas, which can progress into anaplastic astrocytoma and then glioblastoma through gain of other genetic abnormalities such as loss of CDKN2A or RB1, followed by loss of PTEN (Nozaki et al., 1999; 11550308). There are no approved therapies to address TP53 mutation or loss. However, tumors with TP53 loss of function alterations may be sensitive to the WEE1 inhibitor adavosertib (Hirai et al., 2010; 20107315, Bridges et al., 2011; 21799033, Rajeshkumar et al., 2011; 21389100, Osman et al., 2015; 25504633) or p53 gene therapy such as SGT53 (Xu et al., 2002; 12489850, Xu et al., 2001; 11713371, Camp et al., 2013; 23470564, Kim et al., 2015; 25240597, Pirollo et al., 2016; 27357628, Leung et al., 2021; ASCO Abstract 4139). In a Phase 1 study, adavosertib in combination with gemcitabine, cisplatin, or carboplatin elicited PRs in 9.7% and SDs in 53% of patients with solid tumors; the response rate was 21% (4/19) for patients with TP53 mutations versus 12% (4/33) for patients who were TP53 wildtype (Leijen et al., 2016; 27601554). A Phase 2 trial of adavosertib in combination with chemotherapy (gemcitabine, carboplatin, paclitaxel, or doxorubicin) reported a 32% (30/94, 3 CR) ORR and a 73% (69/94) DCR for patients with platinum-refractory TP53-mutated ovarian, Fallopian tube, or peritoneal cancer (Moore et al., 2019; ASCO Abstract 5513). A smaller Phase 2 trial of adavosertib in combination with carboplatin achieved a 43% (9/21, 1 CR) ORR and a 76% (16/21) DCR for patients with platinum-refractory TP53-mutated ovarian cancer (Leijen et al., 2016; 27998224). The combination of adavosertib with paclitaxel and carboplatin for patients with TP53-mutated ovarian cancer also significantly increased PFS compared with paclitaxel and carboplatin alone (Oza et al., 2015; ASCO Abstract 5506). In the Phase 2 VIKTORY trial, patients with TP53-mutated metastatic and/or recurrent gastric cancer experienced a 24% (6/25) ORR with adavosertib combined with paclitaxel (Lee et al., 2019; 31315834). A Phase 1 trial of neoadjuvant adavosertib in combination with cisplatin and docetaxel for head and neck squamous cell carcinoma (HNSCC) elicited a 71% (5/7) response rate for patients with TP53 alterations (Mendez et al., 2018; 29535125). The Phase 2 FOCUS4-C trial for patients with TP53- and RAS-mutated colorectal cancer reported improvement in PFS (3.61 vs. 1.87 months, HR=0.35, p=0.0022), but not OS (14.0 vs 12.8 months, p=0.93), following adavosertib treatment compared with active monitoring (Seligmann et al., 2021; 34538072). In a Phase 1b clinical trial of SGT-53 in combination with docetaxel for patients with solid tumors, 75% (9/12) of evaluable patients experienced clinical benefit, including 2 confirmed and 1 unconfirmed PRs and 2 instances of SD with significant tumor shrinkage (Pirollo et al., 2016; 27357628). Missense mutations leading to TP53 inactivation may be sensitive to therapies that reactivate mutated p53 such as eprenetapopt. In a Phase 1b trial for patients with p53-positive high-grade serous ovarian cancer, eprenetapopt combined with carboplatin and pegylated liposomal doxorubicin achieved a 52% (11/21) response rate and 100% DCR (Gourley et al., 2016; ASCO Abstract 5571). A Phase 1 trial of eprenetapopt with pembrolizumab for patients with solid tumors reported an ORR of 10% (3/29) (Park et al., 2022; 36084396). It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here. Germline mutations in TP53 are associated with the very rare autosomal dominant disorder Li-Fraumeni syndrome and the early onset of many cancers (Bougeard et al., 2015; 26014290, Sorrell et al., 2013; 23355100, Nichols et al., 2001; 11219776), including sarcomas (Kleihues et al., 1997; 9006316, Gonzalez et al., 2009; 19204208). Estimates for the prevalence of germline TP53 mutations in the general population range from 1:5,000 (Lalloo et al., 2003; 12672316) to 1:20,000 (Gonzalez et al., 2009; 19204208). For pathogenic TP53 mutations identified during tumor sequencing, the rate of germline mutations was 1% in the overall population and 6% in tumors arising before age 30 (Mandelker et al., 2019; 31050713). In the appropriate clinical context, germline testing of TP53 is recommended. Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age-related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838, Xie et al., 2014; 25326804, Acuna-Hidalgo et al., 2017; 28669404, Severson et al., 2018; 29678827, Fuster et al., 2018; 29420212). CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838). Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease (Steensma., 2018; 30504320). Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH (Severson et al., 2018; 29678827, Chabon et al., 2020; 32269342, Razavi et al., 2019; 31768066). Patient-matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.</Interpretation>
              <Include>true</Include>
              <ClinicalTrialNote />
              <Therapies />
              <ReferenceLinks />
              <ClinicalTrialLinks />
            </Alteration>
          </Alterations>
          <ReferenceLinks />
        </Gene>
        <Gene>
          <Name>Tumor Mutation Burden</Name>
          <Include>true</Include>
          <Alterations>
            <Alteration>
              <Name>00</Name>
              <AlterationProperties>
                <AlterationProperty isEquivocal="false" name="00" />
              </AlterationProperties>
              <Interpretation>Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein-coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide-based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). This sample harbors a TMB below levels that would be predicted to be associated with sensitivity to PD-1- or PD-L1-targeting immune checkpoint inhibitors, alone or in combination with other agents (Touat et al., 2020; 32322066, Kamiya-Matsuoka et al., 2019; ESMO Abstract 393O, Zhao et al., 2019; 30742119, Samstein et al., 2019; 30643254, Bouffet et al., 2016; 27001570, Johanns et al., 2016; 27683556, Lukas et al., 2018; 30073642). Glioblastoma (GBM) harbors a median TMB of 2.7 mutations per megabase (muts/Mb), and 4.2% of cases have high TMB (&gt;20 muts/Mb)(FMI-Chalmers et al., 2017; 28420421). For pediatric patients, high TMB has been reported in a subset of high-grade gliomas, frequently in association with mutations in mismatch repair or proofreading genes and in TP53, whereas BRAF alterations or other oncogene fusions were observed more frequently in brain tumors harboring low TMB (Patel et al., 2020; 32386112, Johnson et al., 2017; 28912153). Increased TMB has been reported to correlate with higher tumor grade in glioma (Draaisma et al., 2015; 26699864) and glioblastoma (GBM) tissue samples with biallelic mismatch repair deficiency (bMMRD) (Bouffet et al., 2016; 27001570), as well as with shorter OS of patients with diffuse glioma (Wang et al., 2020; 32164609). On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti-PD-L1 (Legrand et al., 2018; ASCO Abstract 12000, Samstein et al., 2019; 30643254, Goodman et al., 2017; 28835386, Goodman et al., 2019; 31405947), anti-PD-1 therapies (Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947), and combination nivolumab and ipilimumab (Ready et al., 2019; 30785829, Hellmann et al., 2018; 29658845, Hellmann et al., 2018; 29657128, Rizvi et al., 2017; WCLC Abstract 1106, Hellmann et al., 2018; 29731394, Rozeman et al., 2021; 33558721, Hodi et al., 2019; AACR abstract CT037, Lee et al., 2019; ASCO Abstract 641, Sharma et al., 2020; 32916128). In glioma, a lack of association between TMB and clinical benefit from immune checkpoint inhibitors has been reported (Kamiya-Matsuoka et al., 2019; ESMO Abstract 393O, Zhao et al., 2019; 30742119, Samstein et al., 2019; 30643254, Touat et al., 2020; 32322066). However, multiple case studies have reported that patients with ultramutated gliomas driven by POLE mutations have benefited from treatment with anti-PD-1 (Bouffet et al., 2016; 27001570, Johanns et al., 2016; 27683556) or anti-PD-L1 (Lukas et al., 2018; 30073642) therapies. Therefore, although increased TMB alone may not be a strong biomarker for PD-1 or PD-L1 inhibitors in this cancer type, these agents may have efficacy for patients with glioma harboring both high TMB and POLE mutation.</Interpretation>
              <Include>true</Include>
              <ClinicalTrialNote />
              <Therapies />
              <ReferenceLinks />
              <ClinicalTrialLinks />
            </Alteration>
          </Alterations>
          <ReferenceLinks />
        </Gene>
      </Genes>
      <Trials>
        <Trial>
          <Gene>CD274 (PD-L1)</Gene>
          <Alteration>amplification</Alteration>
          <Title>KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors</Title>
          <StudyPhase>PHASE null</StudyPhase>
          <Target>ADORA2A, CD73, PD-1</Target>
          <Locations>Taipei (Taiwan), Shatin, New Territories (Hong Kong), Sunto Gun (Japan), Singapore (Singapore), Milano (Italy), Barcelona (Spain), California, Illinois, Toronto (Canada), Missouri</Locations>
          <NCTID>NCT04237649</NCTID>
          <Note>CD274 (PD-L1) amplification or rearrangements that disrupt the 3' untranslated region (UTR) may promote PD-1 signaling and inhibit the antitumor immune response. Antibodies that block the interaction of PD-L1 and PD-1 (alone, in combination with anti-CTLA-4, or bispecific PD-1/CTLA-4 antibodies) may therefore be beneficial to release the antitumor immune response. Furthermore, JAK2 inhibitors may be relevant, as they may reduce PD-L1 expression.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>CD274 (PD-L1)</Gene>
          <Alteration>amplification</Alteration>
          <Title>Study of BGB-A1217 in Combination With Tislelizumab in Advanced Solid Tumors</Title>
          <StudyPhase>PHASE 1</StudyPhase>
          <Target>PD-1, TIGIT</Target>
          <Locations>Taipei (Taiwan), Taoyuan (Taiwan), Hualien City (Taiwan), Taichung (Taiwan), Fujian (China), Hangzhou (China), Shanghai (China), Hefei (China), Guangdong (China), Changsha (China)</Locations>
          <NCTID>NCT04047862</NCTID>
          <Note>CD274 (PD-L1) amplification or rearrangements that disrupt the 3' untranslated region (UTR) may promote PD-1 signaling and inhibit the antitumor immune response. Antibodies that block the interaction of PD-L1 and PD-1 (alone, in combination with anti-CTLA-4, or bispecific PD-1/CTLA-4 antibodies) may therefore be beneficial to release the antitumor immune response. Furthermore, JAK2 inhibitors may be relevant, as they may reduce PD-L1 expression.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>CD274 (PD-L1)</Gene>
          <Alteration>amplification</Alteration>
          <Title>Nanatinostat Plus Valganciclovir in Patients With Advanced EBV+ Solid Tumors, and in Combination With Pembrolizumab in EBV+ RM-NPC</Title>
          <StudyPhase>PHASE 1/2</StudyPhase>
          <Target>HDAC, PD-1</Target>
          <Locations>Taipei City (Taiwan), Taipei (Taiwan), Taoyuan City (Taiwan), Sha Tin (Hong Kong), Hong Kong (Hong Kong), Seoul (Korea, Republic of), Kuching (Malaysia), Kuala Lumpur (Malaysia), Singapore (Singapore), Blacktown (Australia)</Locations>
          <NCTID>NCT05166577</NCTID>
          <Note>CD274 (PD-L1) amplification or rearrangements that disrupt the 3' untranslated region (UTR) may promote PD-1 signaling and inhibit the antitumor immune response. Antibodies that block the interaction of PD-L1 and PD-1 (alone, in combination with anti-CTLA-4, or bispecific PD-1/CTLA-4 antibodies) may therefore be beneficial to release the antitumor immune response. Furthermore, JAK2 inhibitors may be relevant, as they may reduce PD-L1 expression.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>CD274 (PD-L1)</Gene>
          <Alteration>amplification</Alteration>
          <Title>A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors</Title>
          <StudyPhase>PHASE 1</StudyPhase>
          <Target>PD-L1, PD-1, CTLA-4</Target>
          <Locations>Taipei (Taiwan), Tainan (Taiwan), Cheongju-si (Korea, Republic of), Incheon (Korea, Republic of), Seoul (Korea, Republic of), Gyeonggi-do (Korea, Republic of), Melbourne (Australia), Amsterdam (Netherlands), Ravenna (Italy), Meldola (Italy)</Locations>
          <NCTID>NCT03530397</NCTID>
          <Note>CD274 (PD-L1) amplification or rearrangements that disrupt the 3' untranslated region (UTR) may promote PD-1 signaling and inhibit the antitumor immune response. Antibodies that block the interaction of PD-L1 and PD-1 (alone, in combination with anti-CTLA-4, or bispecific PD-1/CTLA-4 antibodies) may therefore be beneficial to release the antitumor immune response. Furthermore, JAK2 inhibitors may be relevant, as they may reduce PD-L1 expression.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>CD274 (PD-L1)</Gene>
          <Alteration>amplification</Alteration>
          <Title>Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Participants With Locally Advanced or Metastatic Solid Tumors</Title>
          <StudyPhase>PHASE 1</StudyPhase>
          <Target>PD-1, GARP</Target>
          <Locations>Taichung City (Taiwan), Taipei City (Taiwan), Seoul (Korea, Republic of), Chuo-ku (Japan), Kashiwa-shi (Japan), South Brisbane (Australia), Camperdown (Australia), Ramat Gan (Israel), Tel Aviv-Yafo (Israel), Haifa (Israel)</Locations>
          <NCTID>NCT03821935</NCTID>
          <Note>CD274 (PD-L1) amplification or rearrangements that disrupt the 3' untranslated region (UTR) may promote PD-1 signaling and inhibit the antitumor immune response. Antibodies that block the interaction of PD-L1 and PD-1 (alone, in combination with anti-CTLA-4, or bispecific PD-1/CTLA-4 antibodies) may therefore be beneficial to release the antitumor immune response. Furthermore, JAK2 inhibitors may be relevant, as they may reduce PD-L1 expression.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>CD274 (PD-L1)</Gene>
          <Alteration>amplification</Alteration>
          <Title>Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors</Title>
          <StudyPhase>PHASE 1</StudyPhase>
          <Target>PD-1, OX40</Target>
          <Locations>Changhua (Taiwan), Taipei (Taiwan), Tianan (Taiwan), Hangzhou (China), Shanghai (China), Changsha (China), Wuhan (China), Linyi (China), Gyeonggi-do (Korea, Republic of), Gyeongju (Korea, Republic of)</Locations>
          <NCTID>NCT04215978</NCTID>
          <Note>CD274 (PD-L1) amplification or rearrangements that disrupt the 3' untranslated region (UTR) may promote PD-1 signaling and inhibit the antitumor immune response. Antibodies that block the interaction of PD-L1 and PD-1 (alone, in combination with anti-CTLA-4, or bispecific PD-1/CTLA-4 antibodies) may therefore be beneficial to release the antitumor immune response. Furthermore, JAK2 inhibitors may be relevant, as they may reduce PD-L1 expression.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>CD274 (PD-L1)</Gene>
          <Alteration>amplification</Alteration>
          <Title>Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors</Title>
          <StudyPhase>PHASE 1/2</StudyPhase>
          <Target>PD-L1, FGFRs, RET, PDGFRA, VEGFRs, KIT, FLT3, CSF1R</Target>
          <Locations>Hangzhou (China), Shanghai (China), Dongguan (China), Guangzhou (China), Zhuhai (China), Benbu (China), Zhengzhou (China), Jinan (China), Dalian (China), Tianjin (China)</Locations>
          <NCTID>NCT05024214</NCTID>
          <Note>CD274 (PD-L1) amplification or rearrangements that disrupt the 3' untranslated region (UTR) may promote PD-1 signaling and inhibit the antitumor immune response. Antibodies that block the interaction of PD-L1 and PD-1 (alone, in combination with anti-CTLA-4, or bispecific PD-1/CTLA-4 antibodies) may therefore be beneficial to release the antitumor immune response. Furthermore, JAK2 inhibitors may be relevant, as they may reduce PD-L1 expression.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>CD274 (PD-L1)</Gene>
          <Alteration>amplification</Alteration>
          <Title>Study of BGB-A425 in Combination With Tislelizumab in Advanced Solid Tumors</Title>
          <StudyPhase>PHASE 1/2</StudyPhase>
          <Target>PD-1, TIM-3</Target>
          <Locations>Busan (Korea, Republic of), Ulsan (Korea, Republic of), Cheongju (Korea, Republic of), Suwon (Korea, Republic of), Incheon (Korea, Republic of), Seongnam (Korea, Republic of), Seoul (Korea, Republic of), Goyang (Korea, Republic of), Perth (Australia), Hervey Bay (Australia)</Locations>
          <NCTID>NCT03744468</NCTID>
          <Note>CD274 (PD-L1) amplification or rearrangements that disrupt the 3' untranslated region (UTR) may promote PD-1 signaling and inhibit the antitumor immune response. Antibodies that block the interaction of PD-L1 and PD-1 (alone, in combination with anti-CTLA-4, or bispecific PD-1/CTLA-4 antibodies) may therefore be beneficial to release the antitumor immune response. Furthermore, JAK2 inhibitors may be relevant, as they may reduce PD-L1 expression.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>CD274 (PD-L1)</Gene>
          <Alteration>amplification</Alteration>
          <Title>Hypofractionated Radiotherapy Combined With PD-1 Inhibitor Sequential GM-CSF and IL-2 for the Treatment of Advanced Refractory Solid Tumors (PRaG2.0)</Title>
          <StudyPhase>PHASE 2</StudyPhase>
          <Target>PD-1</Target>
          <Locations>Hangzhou (China), Suzhou (China), Wuxi (China), Hefei (China), Xuzhou (China)</Locations>
          <NCTID>NCT04892498</NCTID>
          <Note>CD274 (PD-L1) amplification or rearrangements that disrupt the 3' untranslated region (UTR) may promote PD-1 signaling and inhibit the antitumor immune response. Antibodies that block the interaction of PD-L1 and PD-1 (alone, in combination with anti-CTLA-4, or bispecific PD-1/CTLA-4 antibodies) may therefore be beneficial to release the antitumor immune response. Furthermore, JAK2 inhibitors may be relevant, as they may reduce PD-L1 expression.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>CD274 (PD-L1)</Gene>
          <Alteration>amplification</Alteration>
          <Title>A Study of AK109 Combined With AK104 in Patients With Advanced Solid Tumors</Title>
          <StudyPhase>PHASE 1/2</StudyPhase>
          <Target>PD-1, CTLA-4, VEGFR2</Target>
          <Locations>Hangzhou (China)</Locations>
          <NCTID>NCT05142423</NCTID>
          <Note>CD274 (PD-L1) amplification or rearrangements that disrupt the 3' untranslated region (UTR) may promote PD-1 signaling and inhibit the antitumor immune response. Antibodies that block the interaction of PD-L1 and PD-1 (alone, in combination with anti-CTLA-4, or bispecific PD-1/CTLA-4 antibodies) may therefore be beneficial to release the antitumor immune response. Furthermore, JAK2 inhibitors may be relevant, as they may reduce PD-L1 expression.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>NF1</Gene>
          <Alteration>R1276*Y489*</Alteration>
          <Title>Efficacy and Safety of Targeted Precision Therapy in Refractory Tumor With Druggable Molecular Event</Title>
          <StudyPhase>PHASE 2</StudyPhase>
          <Target>EGFR, ERBB4, ERBB2, PARP, mTOR, MET, ROS1, RET, VEGFRs, BRAF, CDK4, CDK6</Target>
          <Locations>Shanghai (China)</Locations>
          <NCTID>NCT03239015</NCTID>
          <Note>On the basis of clinical evidence and strong preclinical evidence, NF1 inactivation may predict sensitivity to MEK inhibitors. Limited clinical data and strong preclinical data indicate that loss or inactivation of NF1 may also predict sensitivity to mTOR inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>NF1</Gene>
          <Alteration>R1276*Y489*</Alteration>
          <Title>Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors</Title>
          <StudyPhase>PHASE 2</StudyPhase>
          <Target>mTOR, FGFRs, RET, PDGFRA, VEGFRs, KIT, MEK</Target>
          <Locations>Guangzhou (China)</Locations>
          <NCTID>NCT04803318</NCTID>
          <Note>On the basis of clinical evidence and strong preclinical evidence, NF1 inactivation may predict sensitivity to MEK inhibitors. Limited clinical data and strong preclinical data indicate that loss or inactivation of NF1 may also predict sensitivity to mTOR inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>NF1</Gene>
          <Alteration>R1276*Y489*</Alteration>
          <Title>DAY101 Monotherapy or in Combination With Other Therapies for Patients With Solid Tumors</Title>
          <StudyPhase>PHASE 1/2</StudyPhase>
          <Target>BRAF, MEK</Target>
          <Locations>Busan (Korea, Republic of), Seoul (Korea, Republic of), Clayton (Australia), Edegem (Belgium), Oregon, Barcelona (Spain), Madrid (Spain), California, Colorado</Locations>
          <NCTID>NCT04985604</NCTID>
          <Note>On the basis of clinical evidence and strong preclinical evidence, NF1 inactivation may predict sensitivity to MEK inhibitors. Limited clinical data and strong preclinical data indicate that loss or inactivation of NF1 may also predict sensitivity to mTOR inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>NF1</Gene>
          <Alteration>R1276*Y489*</Alteration>
          <Title>A Study of Sirolimus for Injection (Albumin Bound) in Patients With Advanced Solid Tumors</Title>
          <StudyPhase>PHASE 1</StudyPhase>
          <Target>mTOR</Target>
          <Locations>Tianjin (China)</Locations>
          <NCTID>NCT05125523</NCTID>
          <Note>On the basis of clinical evidence and strong preclinical evidence, NF1 inactivation may predict sensitivity to MEK inhibitors. Limited clinical data and strong preclinical data indicate that loss or inactivation of NF1 may also predict sensitivity to mTOR inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>NF1</Gene>
          <Alteration>R1276*Y489*</Alteration>
          <Title>Study of the Safety and Pharmacokinetics of BGB-283 and PD-0325901 in Patients With Advanced or Refractory Solid Tumors</Title>
          <StudyPhase>PHASE 1/2</StudyPhase>
          <Target>RAFs, EGFR, MEK</Target>
          <Locations>Nedlands (Australia), Blacktown (Australia), Randwick (Australia), Melbourne (Australia), California, Texas</Locations>
          <NCTID>NCT03905148</NCTID>
          <Note>On the basis of clinical evidence and strong preclinical evidence, NF1 inactivation may predict sensitivity to MEK inhibitors. Limited clinical data and strong preclinical data indicate that loss or inactivation of NF1 may also predict sensitivity to mTOR inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>NF1</Gene>
          <Alteration>R1276*Y489*</Alteration>
          <Title>Mirdametinib + BGB-3245 in Advanced Solid Tumors</Title>
          <StudyPhase>PHASE 1/2</StudyPhase>
          <Target>BRAF, MEK</Target>
          <Locations>Waratah (Australia), Melbourne (Australia), California, Ohio, Massachusetts, Texas, Connecticut, Florida</Locations>
          <NCTID>NCT05580770</NCTID>
          <Note>On the basis of clinical evidence and strong preclinical evidence, NF1 inactivation may predict sensitivity to MEK inhibitors. Limited clinical data and strong preclinical data indicate that loss or inactivation of NF1 may also predict sensitivity to mTOR inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>NF1</Gene>
          <Alteration>R1276*Y489*</Alteration>
          <Title>JAB-3312 Activity in Adult Patients With Advanced Solid Tumors</Title>
          <StudyPhase>PHASE 1/2</StudyPhase>
          <Target>MEK, SHP2, PD-1, EGFR, KRAS</Target>
          <Locations>Utah, California, Arizona, Minnesota, Illinois, Michigan, Oklahoma, Missouri, Indiana, Connecticut</Locations>
          <NCTID>NCT04720976</NCTID>
          <Note>On the basis of clinical evidence and strong preclinical evidence, NF1 inactivation may predict sensitivity to MEK inhibitors. Limited clinical data and strong preclinical data indicate that loss or inactivation of NF1 may also predict sensitivity to mTOR inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>NF1</Gene>
          <Alteration>R1276*Y489*</Alteration>
          <Title>COAST Therapy in Advanced Solid Tumors and Prostate Cancer</Title>
          <StudyPhase>PHASE 1/2</StudyPhase>
          <Target>DDR2, ABL, SRC, KIT, mTOR</Target>
          <Locations>South Carolina</Locations>
          <NCTID>NCT05036226</NCTID>
          <Note>On the basis of clinical evidence and strong preclinical evidence, NF1 inactivation may predict sensitivity to MEK inhibitors. Limited clinical data and strong preclinical data indicate that loss or inactivation of NF1 may also predict sensitivity to mTOR inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>NF1</Gene>
          <Alteration>R1276*Y489*</Alteration>
          <Title>The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs</Title>
          <StudyPhase>PHASE 2</StudyPhase>
          <Target>BRAF, VEGFRs, RET, KIT, ERBB2, TRKB, ALK, TRKC, ROS1, TRKA, SMO, PD-L1, MEK, CDK4, CDK6</Target>
          <Locations>Kuopio (Finland), Helsinki (Finland), Tampere (Finland), Turku (Finland)</Locations>
          <NCTID>NCT05159245</NCTID>
          <Note>On the basis of clinical evidence and strong preclinical evidence, NF1 inactivation may predict sensitivity to MEK inhibitors. Limited clinical data and strong preclinical data indicate that loss or inactivation of NF1 may also predict sensitivity to mTOR inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>NF1</Gene>
          <Alteration>R1276*Y489*</Alteration>
          <Title>Improving Public Cancer Care by Implementing Precision Medicine in Norway</Title>
          <StudyPhase>PHASE 2</StudyPhase>
          <Target>PD-L1, VEGFA, ERBB2, ALK, RET, PARP, SMO, TRKB, TRKC, ROS1, TRKA, MEK, BRAF, PI3K-alpha, FGFR1, FGFR2, FGFR3, MET, KIT, ABL</Target>
          <Locations>Tromsø (Norway), Bodø (Norway), Hamar (Norway), Oslo (Norway), Fredrikstad (Norway), Drammen (Norway), Trondheim (Norway), Skien (Norway), Førde (Norway), Bergen (Norway)</Locations>
          <NCTID>NCT04817956</NCTID>
          <Note>On the basis of clinical evidence and strong preclinical evidence, NF1 inactivation may predict sensitivity to MEK inhibitors. Limited clinical data and strong preclinical data indicate that loss or inactivation of NF1 may also predict sensitivity to mTOR inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>PDCD1LG2 (PD-L2)</Gene>
          <Alteration>amplification</Alteration>
          <Title>KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors</Title>
          <StudyPhase>PHASE null</StudyPhase>
          <Target>ADORA2A, CD73, PD-1</Target>
          <Locations>Taipei (Taiwan), Shatin, New Territories (Hong Kong), Sunto Gun (Japan), Singapore (Singapore), Milano (Italy), Barcelona (Spain), California, Illinois, Toronto (Canada), Missouri</Locations>
          <NCTID>NCT04237649</NCTID>
          <Note>PDCD1LG2 (PD-L2) amplification may promote PD-1 signaling and inhibit the anti-tumor immune response. Antibodies that block the interaction of PD-L2 and PD-1 may therefore be beneficial to release the anti-tumor immune response. Furthermore, JAK2 inhibitors may be relevant, because they may reduce PD-L2 expression.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>PDCD1LG2 (PD-L2)</Gene>
          <Alteration>amplification</Alteration>
          <Title>Study of BGB-A1217 in Combination With Tislelizumab in Advanced Solid Tumors</Title>
          <StudyPhase>PHASE 1</StudyPhase>
          <Target>PD-1, TIGIT</Target>
          <Locations>Taipei (Taiwan), Taoyuan (Taiwan), Hualien City (Taiwan), Taichung (Taiwan), Fujian (China), Hangzhou (China), Shanghai (China), Hefei (China), Guangdong (China), Changsha (China)</Locations>
          <NCTID>NCT04047862</NCTID>
          <Note>PDCD1LG2 (PD-L2) amplification may promote PD-1 signaling and inhibit the anti-tumor immune response. Antibodies that block the interaction of PD-L2 and PD-1 may therefore be beneficial to release the anti-tumor immune response. Furthermore, JAK2 inhibitors may be relevant, because they may reduce PD-L2 expression.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>PDCD1LG2 (PD-L2)</Gene>
          <Alteration>amplification</Alteration>
          <Title>Nanatinostat Plus Valganciclovir in Patients With Advanced EBV+ Solid Tumors, and in Combination With Pembrolizumab in EBV+ RM-NPC</Title>
          <StudyPhase>PHASE 1/2</StudyPhase>
          <Target>HDAC, PD-1</Target>
          <Locations>Taipei City (Taiwan), Taipei (Taiwan), Taoyuan City (Taiwan), Sha Tin (Hong Kong), Hong Kong (Hong Kong), Seoul (Korea, Republic of), Kuching (Malaysia), Kuala Lumpur (Malaysia), Singapore (Singapore), Blacktown (Australia)</Locations>
          <NCTID>NCT05166577</NCTID>
          <Note>PDCD1LG2 (PD-L2) amplification may promote PD-1 signaling and inhibit the anti-tumor immune response. Antibodies that block the interaction of PD-L2 and PD-1 may therefore be beneficial to release the anti-tumor immune response. Furthermore, JAK2 inhibitors may be relevant, because they may reduce PD-L2 expression.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>PDCD1LG2 (PD-L2)</Gene>
          <Alteration>amplification</Alteration>
          <Title>A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors</Title>
          <StudyPhase>PHASE 1</StudyPhase>
          <Target>PD-L1, PD-1, CTLA-4</Target>
          <Locations>Taipei (Taiwan), Tainan (Taiwan), Cheongju-si (Korea, Republic of), Incheon (Korea, Republic of), Seoul (Korea, Republic of), Gyeonggi-do (Korea, Republic of), Melbourne (Australia), Amsterdam (Netherlands), Ravenna (Italy), Meldola (Italy)</Locations>
          <NCTID>NCT03530397</NCTID>
          <Note>PDCD1LG2 (PD-L2) amplification may promote PD-1 signaling and inhibit the anti-tumor immune response. Antibodies that block the interaction of PD-L2 and PD-1 may therefore be beneficial to release the anti-tumor immune response. Furthermore, JAK2 inhibitors may be relevant, because they may reduce PD-L2 expression.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>PDCD1LG2 (PD-L2)</Gene>
          <Alteration>amplification</Alteration>
          <Title>Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Participants With Locally Advanced or Metastatic Solid Tumors</Title>
          <StudyPhase>PHASE 1</StudyPhase>
          <Target>PD-1, GARP</Target>
          <Locations>Taichung City (Taiwan), Taipei City (Taiwan), Seoul (Korea, Republic of), Chuo-ku (Japan), Kashiwa-shi (Japan), South Brisbane (Australia), Camperdown (Australia), Ramat Gan (Israel), Tel Aviv-Yafo (Israel), Haifa (Israel)</Locations>
          <NCTID>NCT03821935</NCTID>
          <Note>PDCD1LG2 (PD-L2) amplification may promote PD-1 signaling and inhibit the anti-tumor immune response. Antibodies that block the interaction of PD-L2 and PD-1 may therefore be beneficial to release the anti-tumor immune response. Furthermore, JAK2 inhibitors may be relevant, because they may reduce PD-L2 expression.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>PDCD1LG2 (PD-L2)</Gene>
          <Alteration>amplification</Alteration>
          <Title>Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors</Title>
          <StudyPhase>PHASE 1</StudyPhase>
          <Target>PD-1, OX40</Target>
          <Locations>Changhua (Taiwan), Taipei (Taiwan), Tianan (Taiwan), Hangzhou (China), Shanghai (China), Changsha (China), Wuhan (China), Linyi (China), Gyeonggi-do (Korea, Republic of), Gyeongju (Korea, Republic of)</Locations>
          <NCTID>NCT04215978</NCTID>
          <Note>PDCD1LG2 (PD-L2) amplification may promote PD-1 signaling and inhibit the anti-tumor immune response. Antibodies that block the interaction of PD-L2 and PD-1 may therefore be beneficial to release the anti-tumor immune response. Furthermore, JAK2 inhibitors may be relevant, because they may reduce PD-L2 expression.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>PDCD1LG2 (PD-L2)</Gene>
          <Alteration>amplification</Alteration>
          <Title>Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors</Title>
          <StudyPhase>PHASE 1/2</StudyPhase>
          <Target>PD-L1, FGFRs, RET, PDGFRA, VEGFRs, KIT, FLT3, CSF1R</Target>
          <Locations>Hangzhou (China), Shanghai (China), Dongguan (China), Guangzhou (China), Zhuhai (China), Benbu (China), Zhengzhou (China), Jinan (China), Dalian (China), Tianjin (China)</Locations>
          <NCTID>NCT05024214</NCTID>
          <Note>PDCD1LG2 (PD-L2) amplification may promote PD-1 signaling and inhibit the anti-tumor immune response. Antibodies that block the interaction of PD-L2 and PD-1 may therefore be beneficial to release the anti-tumor immune response. Furthermore, JAK2 inhibitors may be relevant, because they may reduce PD-L2 expression.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>PDCD1LG2 (PD-L2)</Gene>
          <Alteration>amplification</Alteration>
          <Title>Study of BGB-A425 in Combination With Tislelizumab in Advanced Solid Tumors</Title>
          <StudyPhase>PHASE 1/2</StudyPhase>
          <Target>PD-1, TIM-3</Target>
          <Locations>Busan (Korea, Republic of), Ulsan (Korea, Republic of), Cheongju (Korea, Republic of), Suwon (Korea, Republic of), Incheon (Korea, Republic of), Seongnam (Korea, Republic of), Seoul (Korea, Republic of), Goyang (Korea, Republic of), Perth (Australia), Hervey Bay (Australia)</Locations>
          <NCTID>NCT03744468</NCTID>
          <Note>PDCD1LG2 (PD-L2) amplification may promote PD-1 signaling and inhibit the anti-tumor immune response. Antibodies that block the interaction of PD-L2 and PD-1 may therefore be beneficial to release the anti-tumor immune response. Furthermore, JAK2 inhibitors may be relevant, because they may reduce PD-L2 expression.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>PDCD1LG2 (PD-L2)</Gene>
          <Alteration>amplification</Alteration>
          <Title>Hypofractionated Radiotherapy Combined With PD-1 Inhibitor Sequential GM-CSF and IL-2 for the Treatment of Advanced Refractory Solid Tumors (PRaG2.0)</Title>
          <StudyPhase>PHASE 2</StudyPhase>
          <Target>PD-1</Target>
          <Locations>Hangzhou (China), Suzhou (China), Wuxi (China), Hefei (China), Xuzhou (China)</Locations>
          <NCTID>NCT04892498</NCTID>
          <Note>PDCD1LG2 (PD-L2) amplification may promote PD-1 signaling and inhibit the anti-tumor immune response. Antibodies that block the interaction of PD-L2 and PD-1 may therefore be beneficial to release the anti-tumor immune response. Furthermore, JAK2 inhibitors may be relevant, because they may reduce PD-L2 expression.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>PDCD1LG2 (PD-L2)</Gene>
          <Alteration>amplification</Alteration>
          <Title>A Study of AK109 Combined With AK104 in Patients With Advanced Solid Tumors</Title>
          <StudyPhase>PHASE 1/2</StudyPhase>
          <Target>PD-1, CTLA-4, VEGFR2</Target>
          <Locations>Hangzhou (China)</Locations>
          <NCTID>NCT05142423</NCTID>
          <Note>PDCD1LG2 (PD-L2) amplification may promote PD-1 signaling and inhibit the anti-tumor immune response. Antibodies that block the interaction of PD-L2 and PD-1 may therefore be beneficial to release the anti-tumor immune response. Furthermore, JAK2 inhibitors may be relevant, because they may reduce PD-L2 expression.</Note>
          <Include>true</Include>
        </Trial>
      </Trials>
      <References>
        <Reference number="0">
          <ReferenceId>18173375</ReferenceId>
          <FullCitation>Keir ME, et al. Annu. Rev. Immunol. (2008) pmid: 18173375</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="1">
          <ReferenceId>17629517</ReferenceId>
          <FullCitation>Butte MJ, et al. Immunity (2007) pmid: 17629517</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="2">
          <ReferenceId>24497532</ReferenceId>
          <FullCitation>Twa DD, et al. Blood (2014) pmid: 24497532</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="3">
          <ReferenceId>25025450</ReferenceId>
          <FullCitation>Shi M, et al. Am. J. Surg. Pathol. (2014) pmid: 25025450</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="4">
          <ReferenceId>22588877</ReferenceId>
          <FullCitation>Cerami E, et al. Cancer Discov (2012) pmid: 22588877</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="5">
          <ReferenceId>23550210</ReferenceId>
          <FullCitation>Gao J, et al. Sci Signal (2013) pmid: 23550210</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="6">
          <ReferenceId>26546453</ReferenceId>
          <FullCitation>Reardon DA, et al. Cancer Immunol Res (2016) pmid: 26546453</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="7">
          <ReferenceId>23462419</ReferenceId>
          <FullCitation>Zeng J, et al. Int. J. Radiat. Oncol. Biol. Phys. (2013) pmid: 23462419</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="8">
          <ReferenceId>24691018</ReferenceId>
          <FullCitation>Wainwright DA, et al. Clin. Cancer Res. (2014) pmid: 24691018</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="9">
          <ReferenceId>30713802</ReferenceId>
          <FullCitation>Wang ZL, et al. Oncoimmunology (2019) pmid: 30713802</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="10">
          <ReferenceId>29721184</ReferenceId>
          <FullCitation>Takashima Y, et al. Oncotarget (2018) pmid: 29721184</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="11">
          <ReferenceId>25399552</ReferenceId>
          <FullCitation>Robert C, et al. N. Engl. J. Med. (2015) pmid: 25399552</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="12">
          <ReferenceId>25795410</ReferenceId>
          <FullCitation>Weber JS, et al. Lancet Oncol. (2015) pmid: 25795410</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="13">
          <ReferenceId>26027431</ReferenceId>
          <FullCitation>Larkin J, et al. N. Engl. J. Med. (2015) pmid: 26027431</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="14">
          <ReferenceId>25891304</ReferenceId>
          <FullCitation>Postow MA, et al. N. Engl. J. Med. (2015) pmid: 25891304</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="15">
          <ReferenceId>24590637</ReferenceId>
          <FullCitation>Topalian SL, et al. J. Clin. Oncol. (2014) pmid: 24590637</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="16">
          <ReferenceId>26028407</ReferenceId>
          <FullCitation>Brahmer J, et al. N. Engl. J. Med. (2015) pmid: 26028407</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="17">
          <ReferenceId>26412456</ReferenceId>
          <FullCitation>Borghaei H, et al. N. Engl. J. Med. (2015) pmid: 26412456</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="18">
          <ReferenceId>25704439</ReferenceId>
          <FullCitation>Rizvi NA, et al. Lancet Oncol. (2015) pmid: 25704439</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="19">
          <ReferenceId>26406148</ReferenceId>
          <FullCitation>Motzer RJ, et al. N. Engl. J. Med. (2015) pmid: 26406148</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="20">
          <ReferenceId>30524881</ReferenceId>
          <FullCitation>George S, et al. Oncoimmunology (2018) pmid: 30524881</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="21">
          <ReferenceId>26970723</ReferenceId>
          <FullCitation>Fehrenbacher L, et al. Lancet (2016) pmid: 26970723</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="22">
          <ReferenceId>25482239</ReferenceId>
          <FullCitation>Ansell SM, et al. N. Engl. J. Med. (2015) pmid: 25482239</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="23">
          <ReferenceId>20628145</ReferenceId>
          <FullCitation>Green MR, et al. Blood (2010) pmid: 20628145</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="24">
          <ReferenceId>22829094</ReferenceId>
          <FullCitation>Derenzini E, et al. Blood Cancer J (2011) pmid: 22829094</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="25">
          <ReferenceId>20460501</ReferenceId>
          <FullCitation>Benson DM, et al. Blood (2010) pmid: 20460501</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="26">
          <ReferenceId>12218188</ReferenceId>
          <FullCitation>Iwai Y, et al. Proc. Natl. Acad. Sci. U.S.A. (2002) pmid: 12218188</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="27">
          <ReferenceId>17363736</ReferenceId>
          <FullCitation>Liu J, et al. Blood (2007) pmid: 17363736</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="28">
          <ReferenceId>32884129</ReferenceId>
          <FullCitation>Huang RSP, et al. Mod Pathol (2021) pmid: 32884129</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="29">
          <ReferenceId>25079317</ReferenceId>
          <FullCitation>Nature (2014) pmid: 25079317</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="30">
          <ReferenceId>27620277</ReferenceId>
          <FullCitation>George J, et al. Clin. Cancer Res. (2017) pmid: 27620277</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="31">
          <ReferenceId>26323609</ReferenceId>
          <FullCitation>Nduom EK, et al. Neuro-oncology (2016) pmid: 26323609</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="32">
          <ReferenceId>25355681</ReferenceId>
          <FullCitation>Berghoff AS, et al. Neuro-oncology (2015) pmid: 25355681</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="33">
          <ReferenceId>26501438</ReferenceId>
          <FullCitation>Preusser M, et al. Clin. Neuropathol. () pmid: 26501438</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="34">
          <ReferenceId>23986257</ReferenceId>
          <FullCitation>Liu Y, et al. J. Neurosci. (2013) pmid: 23986257</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="35">
          <ReferenceId>27999734</ReferenceId>
          <FullCitation>Wang Z, et al. Oncoimmunology (2016) pmid: 27999734</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="36">
          <ReferenceId>25428504</ReferenceId>
          <FullCitation>Herbst RS, et al. Nature (2014) pmid: 25428504</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="37">
          <ReferenceId>32321714</ReferenceId>
          <FullCitation>Tang B, et al. Clin Cancer Res (2020) pmid: 32321714</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="38">
          <ReferenceId>31236579</ReferenceId>
          <FullCitation>Wang F, et al. Ann Oncol (2019) pmid: 31236579</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="39">
          <ReferenceId>33345750</ReferenceId>
          <FullCitation>Xu H, et al. Tumori (2021) pmid: 33345750</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="40">
          <ReferenceId>34678907</ReferenceId>
          <FullCitation>Jin Y, et al. Medicine (Baltimore) (2021) pmid: 34678907</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="41">
          <ReferenceId>34341578</ReferenceId>
          <FullCitation>Mai HQ, et al. Nat Med (2021) pmid: 34341578</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="42">
          <ReferenceId>33492986</ReferenceId>
          <FullCitation>Wang FH, et al. J Clin Oncol (2021) pmid: 33492986</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="43">
          <ReferenceId>34740921</ReferenceId>
          <FullCitation>Sheng X, et al. Clin Cancer Res (2022) pmid: 34740921</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="44">
          <ReferenceId>27269937</ReferenceId>
          <FullCitation>Massard C, et al. J. Clin. Oncol. (2016) pmid: 27269937</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="45">
          <ReferenceId>27900363</ReferenceId>
          <FullCitation>Gröschel S, et al. Cold Spring Harb Mol Case Stud (2016) pmid: 27900363</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="46">
          <ReferenceId>3291612</ReferenceId>
          <FullCitation>Bauman WA, et al. Am J Med (1988) pmid: 3291612</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="47">
          <ReferenceId>29562145</ReferenceId>
          <FullCitation>Motzer RJ, et al. N. Engl. J. Med. (2018) pmid: 29562145</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="48">
          <ReferenceId>35442766</ReferenceId>
          <FullCitation>Shen L, et al. J Clin Oncol (2022) pmid: 35442766</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="49">
          <ReferenceId>32173464</ReferenceId>
          <FullCitation>Paz-Ares L, et al. J Thorac Oncol (2020) pmid: 32173464</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="50">
          <ReferenceId>1904223</ReferenceId>
          <FullCitation>Hattori S, et al. Biochem. Biophys. Res. Commun. (1991) pmid: 1904223</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="51">
          <ReferenceId>8628317</ReferenceId>
          <FullCitation>Morcos P, et al. Mol. Cell. Biol. (1996) pmid: 8628317</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="52">
          <ReferenceId>2121371</ReferenceId>
          <FullCitation>Ballester R, et al. Cell (1990) pmid: 2121371</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="53">
          <ReferenceId>2116237</ReferenceId>
          <FullCitation>Xu GF, et al. Cell (1990) pmid: 2116237</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="54">
          <ReferenceId>2121370</ReferenceId>
          <FullCitation>Martin GA, et al. Cell (1990) pmid: 2121370</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="55">
          <ReferenceId>22807134</ReferenceId>
          <FullCitation>Thomas L, et al. Hum. Mutat. (2012) pmid: 22807134</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="56">
          <ReferenceId>9300663</ReferenceId>
          <FullCitation>Skuse GR, et al. Hum. Mol. Genet. (1997) pmid: 9300663</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="57">
          <ReferenceId>11258625</ReferenceId>
          <FullCitation>Messiaen LM, et al. Genet. Med. () pmid: 11258625</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="58">
          <ReferenceId>10607834</ReferenceId>
          <FullCitation>Ars E, et al. Hum. Mol. Genet. (2000) pmid: 10607834</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="59">
          <ReferenceId>15863657</ReferenceId>
          <FullCitation>Messiaen LM, et al. J. Med. Genet. (2005) pmid: 15863657</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="60">
          <ReferenceId>8264648</ReferenceId>
          <FullCitation>Poullet P, et al. Mol. Cell. Biol. (1994) pmid: 8264648</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="61">
          <ReferenceId>26061751</ReferenceId>
          <FullCitation>Cancer Genome Atlas Research Network, et al. N. Engl. J. Med. (2015) pmid: 26061751</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="62">
          <ReferenceId>24336570</ReferenceId>
          <FullCitation>Johnson BE, et al. Science (2014) pmid: 24336570</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="63">
          <ReferenceId>24120142</ReferenceId>
          <FullCitation>Brennan CW, et al. Cell (2013) pmid: 24120142</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="64">
          <ReferenceId>18772890</ReferenceId>
          <FullCitation>Nature (2008) pmid: 18772890</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="65">
          <ReferenceId>20129251</ReferenceId>
          <FullCitation>Verhaak RG, et al. Cancer Cell (2010) pmid: 20129251</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="66">
          <ReferenceId>26190195</ReferenceId>
          <FullCitation>Vizcaíno MA, et al. Hum. Pathol. (2015) pmid: 26190195</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="67">
          <ReferenceId>28029918</ReferenceId>
          <FullCitation>Dombi E, et al. N. Engl. J. Med. (2016) pmid: 28029918</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="68">
          <ReferenceId>33903938</ReferenceId>
          <FullCitation>Schalkwijk S, et al. Cancer Chemother Pharmacol (2021) pmid: 33903938</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="69">
          <ReferenceId>36743881</ReferenceId>
          <FullCitation>Hitchen N, et al. Case Rep Oncol (2023) pmid: 36743881</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="70">
          <ReferenceId>33580196</ReferenceId>
          <FullCitation>Nagabushan S, et al. NPJ Precis Oncol (2021) pmid: 33580196</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="71">
          <ReferenceId>36192032</ReferenceId>
          <FullCitation>Hones K, et al. BMJ Case Rep (2022) pmid: 36192032</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="72">
          <ReferenceId>31151904</ReferenceId>
          <FullCitation>Fangusaro J, et al. Lancet Oncol. (2019) pmid: 31151904</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="73">
          <ReferenceId>32780261</ReferenceId>
          <FullCitation>Manoharan N, et al. J Neurooncol (2020) pmid: 32780261</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="74">
          <ReferenceId>33082744</ReferenceId>
          <FullCitation>Awada G, et al. Case Rep Oncol () pmid: 33082744</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="75">
          <ReferenceId>37053535</ReferenceId>
          <FullCitation>Wisinski KB, et al. JCO Precis Oncol (2023) pmid: 37053535</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="76">
          <ReferenceId>32669708</ReferenceId>
          <FullCitation>Middleton G, et al. Nature (2020) pmid: 32669708</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="77">
          <ReferenceId>30563938</ReferenceId>
          <FullCitation>Lowery MA, et al. Clin. Cancer Res. (2019) pmid: 30563938</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="78">
          <ReferenceId>26859683</ReferenceId>
          <FullCitation>Lim SM, et al. Oncotarget (2016) pmid: 26859683</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="79">
          <ReferenceId>25314964</ReferenceId>
          <FullCitation>Weiss B, et al. Neuro-oncology (2015) pmid: 25314964</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="80">
          <ReferenceId>24931142</ReferenceId>
          <FullCitation>Janku F, et al. Oncotarget (2014) pmid: 24931142</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="81">
          <ReferenceId>18164202</ReferenceId>
          <FullCitation>Johannessen CM, et al. Curr. Biol. (2008) pmid: 18164202</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="82">
          <ReferenceId>15937108</ReferenceId>
          <FullCitation>Johannessen CM, et al. Proc. Natl. Acad. Sci. U.S.A. (2005) pmid: 15937108</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="83">
          <ReferenceId>24913553</ReferenceId>
          <FullCitation>Malone CF, et al. Cancer Discov (2014) pmid: 24913553</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="84">
          <ReferenceId>29165669</ReferenceId>
          <FullCitation>Landrum MJ, et al. Nucleic Acids Res. (2018) pmid: 29165669</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="85">
          <ReferenceId>20027112</ReferenceId>
          <FullCitation>Jett K, et al. Genet. Med. (2010) pmid: 20027112</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="86">
          <ReferenceId>22240541</ReferenceId>
          <FullCitation>Patil S, et al. Oncologist (2012) pmid: 22240541</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="87">
          <ReferenceId>23036231</ReferenceId>
          <FullCitation>Evans DG, et al. Clin Sarcoma Res (2012) pmid: 23036231</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="88">
          <ReferenceId>8544190</ReferenceId>
          <FullCitation>Upadhyaya M, et al. J. Med. Genet. (1995) pmid: 8544190</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="89">
          <ReferenceId>19117870</ReferenceId>
          <FullCitation>Williams VC, et al. Pediatrics (2009) pmid: 19117870</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="90">
          <ReferenceId>15748635</ReferenceId>
          <FullCitation>Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="91">
          <ReferenceId>23875803</ReferenceId>
          <FullCitation>Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="92">
          <ReferenceId>12379884</ReferenceId>
          <FullCitation>Pfeifer GP, et al. Oncogene (2002) pmid: 12379884</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="93">
          <ReferenceId>25765070</ReferenceId>
          <FullCitation>Rizvi NA, et al. Science (2015) pmid: 25765070</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="94">
          <ReferenceId>29452419</ReferenceId>
          <FullCitation>Choi S, et al. Neuro-oncology (2018) pmid: 29452419</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="95">
          <ReferenceId>23636398</ReferenceId>
          <FullCitation>Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="96">
          <ReferenceId>23447401</ReferenceId>
          <FullCitation>Briggs S, et al. J. Pathol. (2013) pmid: 23447401</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="97">
          <ReferenceId>24583393</ReferenceId>
          <FullCitation>Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="98">
          <ReferenceId>22810696</ReferenceId>
          <FullCitation>Nature (2012) pmid: 22810696</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="99">
          <ReferenceId>25568919</ReferenceId>
          <FullCitation>Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="100">
          <ReferenceId>32322066</ReferenceId>
          <FullCitation>Touat M, et al. Nature (2020) pmid: 32322066</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="101">
          <ReferenceId>30742119</ReferenceId>
          <FullCitation>Zhao J, et al. Nat. Med. (2019) pmid: 30742119</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="102">
          <ReferenceId>30643254</ReferenceId>
          <FullCitation>Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="103">
          <ReferenceId>27001570</ReferenceId>
          <FullCitation>Bouffet E, et al. J. Clin. Oncol. (2016) pmid: 27001570</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="104">
          <ReferenceId>27683556</ReferenceId>
          <FullCitation>Johanns TM, et al. Cancer Discov (2016) pmid: 27683556</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="105">
          <ReferenceId>30073642</ReferenceId>
          <FullCitation>Lukas RV, et al. J. Neurooncol. (2018) pmid: 30073642</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="106">
          <ReferenceId>28420421</ReferenceId>
          <FullCitation>Chalmers ZR, et al. Genome Med (2017) pmid: 28420421</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="107">
          <ReferenceId>32386112</ReferenceId>
          <FullCitation>Patel RR, et al. Pediatr Blood Cancer (2020) pmid: 32386112</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="108">
          <ReferenceId>28912153</ReferenceId>
          <FullCitation>Johnson A, et al. Oncologist (2017) pmid: 28912153</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="109">
          <ReferenceId>26699864</ReferenceId>
          <FullCitation>Draaisma K, et al. Acta Neuropathol Commun (2015) pmid: 26699864</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="110">
          <ReferenceId>32164609</ReferenceId>
          <FullCitation>Wang L, et al. BMC Cancer (2020) pmid: 32164609</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="111">
          <ReferenceId>28835386</ReferenceId>
          <FullCitation>Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="112">
          <ReferenceId>31405947</ReferenceId>
          <FullCitation>Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="113">
          <ReferenceId>30309915</ReferenceId>
          <FullCitation>Cristescu R, et al. Science (2018) pmid: 30309915</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="114">
          <ReferenceId>30785829</ReferenceId>
          <FullCitation>Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="115">
          <ReferenceId>29658845</ReferenceId>
          <FullCitation>Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="116">
          <ReferenceId>29657128</ReferenceId>
          <FullCitation>Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="117">
          <ReferenceId>29731394</ReferenceId>
          <FullCitation>Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="118">
          <ReferenceId>33558721</ReferenceId>
          <FullCitation>Rozeman EA, et al. Nat Med (2021) pmid: 33558721</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="119">
          <ReferenceId>32916128</ReferenceId>
          <FullCitation>Sharma P, et al. Cancer Cell (2020) pmid: 32916128</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="120">
          <ReferenceId>19935675</ReferenceId>
          <FullCitation>Brown CJ, et al. Nat. Rev. Cancer (2009) pmid: 19935675</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="121">
          <ReferenceId>22089350</ReferenceId>
          <FullCitation>Jha P, et al. Diagn. Mol. Pathol. (2011) pmid: 22089350</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="122">
          <ReferenceId>15914282</ReferenceId>
          <FullCitation>Uno M, et al. Cancer Lett. (2005) pmid: 15914282</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="123">
          <ReferenceId>16711514</ReferenceId>
          <FullCitation>Uno M, et al. Int. J. Biol. Markers () pmid: 16711514</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="124">
          <ReferenceId>22844452</ReferenceId>
          <FullCitation>Lass U, et al. PLoS ONE (2012) pmid: 22844452</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="125">
          <ReferenceId>23009112</ReferenceId>
          <FullCitation>Faria MH, et al. APMIS (2012) pmid: 23009112</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="126">
          <ReferenceId>24358143</ReferenceId>
          <FullCitation>Milinkovic V, et al. PLoS ONE (2013) pmid: 24358143</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="127">
          <ReferenceId>23613880</ReferenceId>
          <FullCitation>Galatro TF, et al. PLoS ONE (2013) pmid: 23613880</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="128">
          <ReferenceId>11939587</ReferenceId>
          <FullCitation>Schmidt MC, et al. J. Neuropathol. Exp. Neurol. (2002) pmid: 11939587</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="129">
          <ReferenceId>11550308</ReferenceId>
          <FullCitation>Nozaki M, et al. Neuro-oncology (1999) pmid: 11550308</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="130">
          <ReferenceId>20107315</ReferenceId>
          <FullCitation>Hirai H, et al. Cancer Biol. Ther. (2010) pmid: 20107315</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="131">
          <ReferenceId>21799033</ReferenceId>
          <FullCitation>Bridges KA, et al. Clin. Cancer Res. (2011) pmid: 21799033</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="132">
          <ReferenceId>21389100</ReferenceId>
          <FullCitation>Rajeshkumar NV, et al. Clin. Cancer Res. (2011) pmid: 21389100</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="133">
          <ReferenceId>25504633</ReferenceId>
          <FullCitation>Osman AA, et al. Mol. Cancer Ther. (2015) pmid: 25504633</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="134">
          <ReferenceId>12489850</ReferenceId>
          <FullCitation>Xu L, et al. Mol. Cancer Ther. (2002) pmid: 12489850</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="135">
          <ReferenceId>11713371</ReferenceId>
          <FullCitation>Xu L, et al. Mol. Med. (2001) pmid: 11713371</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="136">
          <ReferenceId>23470564</ReferenceId>
          <FullCitation>Camp ER, et al. Cancer Gene Ther. (2013) pmid: 23470564</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="137">
          <ReferenceId>25240597</ReferenceId>
          <FullCitation>Kim SS, et al. Nanomedicine (2015) pmid: 25240597</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="138">
          <ReferenceId>27357628</ReferenceId>
          <FullCitation>Pirollo KF, et al. Mol. Ther. (2016) pmid: 27357628</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="139">
          <ReferenceId>27601554</ReferenceId>
          <FullCitation>Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27601554</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="140">
          <ReferenceId>27998224</ReferenceId>
          <FullCitation>Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27998224</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="141">
          <ReferenceId>31315834</ReferenceId>
          <FullCitation>Lee J, et al. Cancer Discov (2019) pmid: 31315834</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="142">
          <ReferenceId>29535125</ReferenceId>
          <FullCitation>Méndez E, et al. Clin. Cancer Res. (2018) pmid: 29535125</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="143">
          <ReferenceId>34538072</ReferenceId>
          <FullCitation>Seligmann JF, et al. J Clin Oncol (2021) pmid: 34538072</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="144">
          <ReferenceId>36084396</ReferenceId>
          <FullCitation>Park H, et al. ESMO Open (2022) pmid: 36084396</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="145">
          <ReferenceId>26014290</ReferenceId>
          <FullCitation>Bougeard G, et al. J. Clin. Oncol. (2015) pmid: 26014290</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="146">
          <ReferenceId>23355100</ReferenceId>
          <FullCitation>Sorrell AD, et al. Mol Diagn Ther (2013) pmid: 23355100</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="147">
          <ReferenceId>11219776</ReferenceId>
          <FullCitation>Nichols KE, et al. Cancer Epidemiol. Biomarkers Prev. (2001) pmid: 11219776</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="148">
          <ReferenceId>9006316</ReferenceId>
          <FullCitation>Kleihues P, et al. Am. J. Pathol. (1997) pmid: 9006316</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="149">
          <ReferenceId>19204208</ReferenceId>
          <FullCitation>Gonzalez KD, et al. J. Clin. Oncol. (2009) pmid: 19204208</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="150">
          <ReferenceId>12672316</ReferenceId>
          <FullCitation>Lalloo F, et al. Lancet (2003) pmid: 12672316</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="151">
          <ReferenceId>31050713</ReferenceId>
          <FullCitation>Mandelker D, et al. Ann. Oncol. (2019) pmid: 31050713</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="152">
          <ReferenceId>25426837</ReferenceId>
          <FullCitation>Jaiswal S, et al. N. Engl. J. Med. (2014) pmid: 25426837</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="153">
          <ReferenceId>25426838</ReferenceId>
          <FullCitation>Genovese G, et al. N. Engl. J. Med. (2014) pmid: 25426838</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="154">
          <ReferenceId>25326804</ReferenceId>
          <FullCitation>Xie M, et al. Nat. Med. (2014) pmid: 25326804</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="155">
          <ReferenceId>28669404</ReferenceId>
          <FullCitation>Acuna-Hidalgo R, et al. Am. J. Hum. Genet. (2017) pmid: 28669404</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="156">
          <ReferenceId>29678827</ReferenceId>
          <FullCitation>Severson EA, et al. Blood (2018) pmid: 29678827</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="157">
          <ReferenceId>29420212</ReferenceId>
          <FullCitation>Fuster JJ, et al. Circ. Res. (2018) pmid: 29420212</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="158">
          <ReferenceId>30504320</ReferenceId>
          <FullCitation>Hematology Am Soc Hematol Educ Program (2018) pmid: 30504320</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="159">
          <ReferenceId>32269342</ReferenceId>
          <FullCitation>Chabon JJ, et al. Nature (2020) pmid: 32269342</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="160">
          <ReferenceId>31768066</ReferenceId>
          <FullCitation>Razavi P, et al. Nat. Med. (2019) pmid: 31768066</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="161">
          <ReferenceId>21442038</ReferenceId>
          <FullCitation>Jatiani SS, et al. Genes Cancer (2010) pmid: 21442038</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="162">
          <ReferenceId>22875628</ReferenceId>
          <FullCitation>Chase A, et al. Haematologica (2013) pmid: 22875628</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="163">
          <ReferenceId>26283544</ReferenceId>
          <FullCitation>Mukthavaram R, et al. J Transl Med (2015) pmid: 26283544</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="164">
          <ReferenceId>25162558</ReferenceId>
          <FullCitation>Baskin R, et al. PLoS ONE (2014) pmid: 25162558</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="165">
          <ReferenceId>24861878</ReferenceId>
          <FullCitation>Zheng Q, et al. Neuro-oncology (2014) pmid: 24861878</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="166">
          <ReferenceId>23838182</ReferenceId>
          <FullCitation>He K, et al. Sci Signal (2013) pmid: 23838182</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="167">
          <ReferenceId>23262510</ReferenceId>
          <FullCitation>Stechishin OD, et al. Neuro-oncology (2013) pmid: 23262510</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="168">
          <ReferenceId>22249692</ReferenceId>
          <FullCitation>Sai K, et al. J. Neurooncol. (2012) pmid: 22249692</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="169">
          <ReferenceId>23079654</ReferenceId>
          <FullCitation>Sturm D, et al. Cancer Cell (2012) pmid: 23079654</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="170">
          <ReferenceId>26517431</ReferenceId>
          <FullCitation>Solomon DA, et al. Brain Pathol. (2016) pmid: 26517431</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="171">
          <ReferenceId>23417712</ReferenceId>
          <FullCitation>Fontebasso AM, et al. Acta Neuropathol (2013) pmid: 23417712</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="172">
          <ReferenceId>22286061</ReferenceId>
          <FullCitation>Schwartzentruber J, et al. Nature (2012) pmid: 22286061</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="173">
          <ReferenceId>25200322</ReferenceId>
          <FullCitation>Venneti S, et al. Acta Neuropathol. (2014) pmid: 25200322</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="174">
          <ReferenceId>22286216</ReferenceId>
          <FullCitation>Wu G, et al. Nat. Genet. (2012) pmid: 22286216</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="175">
          <ReferenceId>25909089</ReferenceId>
          <FullCitation>Hochart A, et al. Ann Clin Transl Neurol (2015) pmid: 25909089</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="176">
          <ReferenceId>27219822</ReferenceId>
          <FullCitation>Joyon N, et al. Neuropathol. Appl. Neurobiol. (2017) pmid: 27219822</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="177">
          <ReferenceId>25389051</ReferenceId>
          <FullCitation>Nguyen AT, et al. Neuropathol. Appl. Neurobiol. (2015) pmid: 25389051</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="178">
          <ReferenceId>25667294</ReferenceId>
          <FullCitation>Mistry M, et al. J. Clin. Oncol. (2015) pmid: 25667294</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="179">
          <ReferenceId>26297251</ReferenceId>
          <FullCitation>Feng J, et al. Hum. Pathol. (2015) pmid: 26297251</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="180">
          <ReferenceId>24162739</ReferenceId>
          <FullCitation>Behjati S, et al. Nat. Genet. (2013) pmid: 24162739</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="181">
          <ReferenceId>28059095</ReferenceId>
          <FullCitation>Kervarrec T, et al. Mod Pathol (2017) pmid: 28059095</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="182">
          <ReferenceId>28899740</ReferenceId>
          <FullCitation>Righi A, et al. Hum Pathol (2017) pmid: 28899740</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="183">
          <ReferenceId>28067913</ReferenceId>
          <FullCitation>Papillon-Cavanagh S, et al. Nat. Genet. (2017) pmid: 28067913</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="184">
          <ReferenceId>27694942</ReferenceId>
          <FullCitation>Park SM, et al. Nat Commun (2016) pmid: 27694942</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="185">
          <ReferenceId>29108308</ReferenceId>
          <FullCitation>Arrillaga-Romany I, et al. Oncotarget (2017) pmid: 29108308</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="186">
          <ReferenceId>30559168</ReferenceId>
          <FullCitation>Prabhu VV, et al. Clin. Cancer Res. (2018) pmid: 30559168</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="187">
          <ReferenceId>34185076</ReferenceId>
          <FullCitation>Louis DN, et al. Neuro Oncol (2021) pmid: 34185076</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="188">
          <ReferenceId>34921008</ReferenceId>
          <FullCitation>Pfister SM, et al. Cancer Discov (2022) pmid: 34921008</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="189">
          <ReferenceId>26337942</ReferenceId>
          <FullCitation>Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="190">
          <ReferenceId>21081928</ReferenceId>
          <FullCitation>You JF, et al. Br. J. Cancer (2010) pmid: 21081928</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="191">
          <ReferenceId>24623249</ReferenceId>
          <FullCitation>Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="192">
          <ReferenceId>9823339</ReferenceId>
          <FullCitation>Boland CR, et al. Cancer Res. (1998) pmid: 9823339</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="193">
          <ReferenceId>15528785</ReferenceId>
          <FullCitation>Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="194">
          <ReferenceId>20420947</ReferenceId>
          <FullCitation>Boland CR, et al. Gastroenterology (2010) pmid: 20420947</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="195">
          <ReferenceId>15331927</ReferenceId>
          <FullCitation>Martinez R, et al. Oncology (2004) pmid: 15331927</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="196">
          <ReferenceId>15672285</ReferenceId>
          <FullCitation>Martinez R, et al. J. Cancer Res. Clin. Oncol. (2005) pmid: 15672285</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="197">
          <ReferenceId>17498554</ReferenceId>
          <FullCitation>Martinez R, et al. Cancer Genet. Cytogenet. (2007) pmid: 17498554</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="198">
          <ReferenceId>12908754</ReferenceId>
          <FullCitation>Szybka M, et al. Clin. Neuropathol. () pmid: 12908754</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="199">
          <ReferenceId>25392179</ReferenceId>
          <FullCitation>Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="200">
          <ReferenceId>26140250</ReferenceId>
          <FullCitation>Kroemer G, et al. Oncoimmunology (2015) pmid: 26140250</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="201">
          <ReferenceId>25949894</ReferenceId>
          <FullCitation>Lal N, et al. Oncoimmunology (2015) pmid: 25949894</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="202">
          <ReferenceId>26028255</ReferenceId>
          <FullCitation>Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="203">
          <ReferenceId>25680375</ReferenceId>
          <FullCitation>Herbst RS, et al. Clin. Cancer Res. (2015) pmid: 25680375</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="204">
          <ReferenceId>32437507</ReferenceId>
          <FullCitation>Reardon DA, et al. JAMA Oncol (2020) pmid: 32437507</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="205">
          <ReferenceId>28500559</ReferenceId>
          <FullCitation>Chamberlain MC, et al. J. Neurooncol. (2017) pmid: 28500559</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="206">
          <ReferenceId>29779086</ReferenceId>
          <FullCitation>Mantica M, et al. J. Neurooncol. (2018) pmid: 29779086</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="207">
          <ReferenceId>25642631</ReferenceId>
          <FullCitation>Shlien A, et al. Nat. Genet. (2015) pmid: 25642631</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="208">
          <ReferenceId>30104292</ReferenceId>
          <FullCitation>AlHarbi M, et al. Oncologist (2018) pmid: 30104292</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="209">
          <ReferenceId>28039369</ReferenceId>
          <FullCitation>Roth P, et al. Neuro-oncology (2017) pmid: 28039369</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="210">
          <ReferenceId>24714771</ReferenceId>
          <FullCitation>Taube JM, et al. Clin. Cancer Res. (2014) pmid: 24714771</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="211">
          <ReferenceId>22658127</ReferenceId>
          <FullCitation>Topalian SL, et al. N. Engl. J. Med. (2012) pmid: 22658127</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="212">
          <ReferenceId>33001143</ReferenceId>
          <FullCitation>Oaknin A, et al. JAMA Oncol (2020) pmid: 33001143</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="213">
          <ReferenceId>29863979</ReferenceId>
          <FullCitation>Migden MR, et al. N. Engl. J. Med. (2018) pmid: 29863979</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="214">
          <ReferenceId>34250480</ReferenceId>
          <FullCitation>McCord M, et al. Neurooncol Adv () pmid: 34250480</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="215">
          <ReferenceId>25891174</ReferenceId>
          <FullCitation>Garon EB, et al. N. Engl. J. Med. (2015) pmid: 25891174</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="216">
          <ReferenceId>26712084</ReferenceId>
          <FullCitation>Herbst RS, et al. Lancet (2016) pmid: 26712084</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="217">
          <ReferenceId>29351920</ReferenceId>
          <FullCitation>Bellone S, et al. Clin. Cancer Res. (2018) pmid: 29351920</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="218">
          <ReferenceId>25344362</ReferenceId>
          <FullCitation>Tolcher AW, et al. Ann. Oncol. (2015) pmid: 25344362</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="219">
          <ReferenceId>28009226</ReferenceId>
          <FullCitation>Miller C, et al. J Neurosurg Pediatr (2017) pmid: 28009226</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="220">
          <ReferenceId>30097824</ReferenceId>
          <FullCitation>Kondyli M, et al. J Neurooncol (2018) pmid: 30097824</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="221">
          <ReferenceId>29369501</ReferenceId>
          <FullCitation>Wagner LM, et al. Pediatr Blood Cancer (2018) pmid: 29369501</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="222">
          <ReferenceId>27810072</ReferenceId>
          <FullCitation>Yde CW, et al. Cancer Genet (2016) pmid: 27810072</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="223">
          <ReferenceId>33939292</ReferenceId>
          <FullCitation>Ronsley R, et al. Cancer Med (2021) pmid: 33939292</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="224">
          <ReferenceId>35945463</ReferenceId>
          <FullCitation>Lucas CG, et al. Acta Neuropathol (2022) pmid: 35945463</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="225">
          <ReferenceId>35715627</ReferenceId>
          <FullCitation>Trippett T, et al. Target Oncol (2022) pmid: 35715627</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="226">
          <ReferenceId>29106665</ReferenceId>
          <FullCitation>Omuro A, et al. Neuro-oncology (2018) pmid: 29106665</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="227">
          <ReferenceId>32627129</ReferenceId>
          <FullCitation>Cacciotti C, et al. J Neurooncol (2020) pmid: 32627129</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="228">
          <ReferenceId>30910787</ReferenceId>
          <FullCitation>Godfrey J, et al. Blood (2019) pmid: 30910787</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="229">
          <ReferenceId>30620668</ReferenceId>
          <FullCitation>Reck M, et al. J. Clin. Oncol. (2019) pmid: 30620668</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="230">
          <ReferenceId>26952546</ReferenceId>
          <FullCitation>Rosenberg JE, et al. Lancet (2016) pmid: 26952546</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="231">
          <ReferenceId>25428503</ReferenceId>
          <FullCitation>Powles T, et al. Nature (2014) pmid: 25428503</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="232">
          <ReferenceId>31780255</ReferenceId>
          <FullCitation>Geoerger B, et al. Lancet Oncol. (2020) pmid: 31780255</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="233">
          <ReferenceId>26755520</ReferenceId>
          <FullCitation>McDermott DF, et al. J. Clin. Oncol. (2016) pmid: 26755520</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="234">
          <ReferenceId>30918950</ReferenceId>
          <FullCitation>Hellmann MD, et al. Ann. Oncol. (2019) pmid: 30918950</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="235">
          <ReferenceId>28339824</ReferenceId>
          <FullCitation>Banerjee A, et al. Neuro-oncology (2017) pmid: 28339824</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="236">
          <ReferenceId>35363510</ReferenceId>
          <FullCitation>Eckstein OS, et al. J Clin Oncol (2022) pmid: 35363510</FullCitation>
          <Include>true</Include>
        </Reference>
      </References>
      <Signatures>
        <Signature>
          <ServerTime>2023-06-06 16:02:04</ServerTime>
          <OpName>Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director</OpName>
          <Text>Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director</Text>
        </Signature>
      </Signatures>
      <reportProperties>
        <reportProperty identifier="QualityControlMetrics" key="MedianCoverageValue">
          <value>836x</value>
        </reportProperty>
        <reportProperty identifier="AdditionalFindings" key="TumorMutationBurdenScore">
          <value>0 Muts/Mb</value>
        </reportProperty>
        <reportProperty identifier="AdditionalFindings" key="MicrosatelliteStatusScore">
          <value>0 fraction-unstable-loci</value>
        </reportProperty>
        <reportProperty identifier="AdditionalFindings" key="LossOfHeterozygosityScore">
          <value>Units Not Reported</value>
        </reportProperty>
        <reportProperty identifier="AdditionalFindings" key="BloodTumorMutationalBurdenScore">
          <value>Units Not Reported</value>
        </reportProperty>
        <reportProperty identifier="AdditionalFindings" key="TumorFractionScore">
          <value>Units Not Reported</value>
        </reportProperty>
      </reportProperties>
      <comments />
      <AAC>
        <Amendmends />
      </AAC>
    </FinalReport>
    <variant-report xmlns="http://foundationmedicine.com/compbio/variant-report-external" disease="BRAIN" disease-ontology="Brain glioblastoma (GBM)" flowcell-analysis="2000029373" gender="female" pathology-diagnosis="Glioblastoma" percent-tumor-nuclei="50" pipeline-version="v3.22.0" purity-assessment="77.37" specimen="ORD-1640271-01*US1564922.01" study="CLINICAL-F1CDx v2" test-request="ORD-1640271-01" test-type="FoundationOneDx" tissue-of-origin="Brain" xsi:schemaLocation="http://foundationmedicine.com/compbio/variant-report-external http://integration.foundationmedicine.com/reporting/variant-report-external-2.2.xsd">
      <samples>
        <sample bait-set="DX2" mean-exon-depth="861.13" name="SQ-US1564922.01-1" nucleic-acid-type="DNA" />
      </samples>
      <quality-control status="Pass" />
      <short-variants>
        <short-variant allele-fraction="0.5118" cds-effect="3826C&gt;T" depth="1102" equivocal="false" functional-effect="nonsense" gene="NF1" percent-reads="51.18" position="chr17:29562746" protein-effect="R1276*" status="known" strand="+" transcript="NM_001042492">
          <dna-evidence sample="SQ-US1564922.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.343" cds-effect="83A&gt;T" depth="516" equivocal="false" functional-effect="missense" gene="H3F3A" percent-reads="34.3" position="chr1:226252135" protein-effect="K28M" status="known" strand="+" transcript="NM_002107">
          <dna-evidence sample="SQ-US1564922.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.3757" cds-effect="3306_3307insGTCGTGCT" depth="378" equivocal="false" functional-effect="frameshift" gene="PIK3C2G" percent-reads="37.57" position="chr12:18691195" protein-effect="Y1103fs*15" status="unknown" strand="+" transcript="NM_004570">
          <dna-evidence sample="SQ-US1564922.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.2753" cds-effect="1467T&gt;A" depth="879" equivocal="false" functional-effect="nonsense" gene="NF1" percent-reads="27.53" position="chr17:29541543" protein-effect="Y489*" status="likely" strand="+" transcript="NM_001042492">
          <dna-evidence sample="SQ-US1564922.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.6191" cds-effect="2T&gt;G" depth="470" equivocal="false" functional-effect="nonsense" gene="TP53" percent-reads="61.91" position="chr17:7578532" protein-effect="M1R" status="known" strand="-" transcript="NM_001126117">
          <dna-evidence sample="SQ-US1564922.01-1" />
        </short-variant>
      </short-variants>
      <copy-number-alterations>
        <copy-number-alteration copy-number="9" equivocal="true" gene="CDKN2A" number-of-exons="5 of 5" position="chr9:21968169-21994453" ratio="2.07" status="unknown" type="amplification">
          <dna-evidence sample="SQ-US1564922.01-1" />
        </copy-number-alteration>
        <copy-number-alteration copy-number="14" equivocal="false" gene="CD274" number-of-exons="7 of 7" position="chr9:5456074-5470632" ratio="3.11" status="known" type="amplification">
          <dna-evidence sample="SQ-US1564922.01-1" />
        </copy-number-alteration>
        <copy-number-alteration copy-number="14" equivocal="false" gene="PDCD1LG2" number-of-exons="6 of 6" position="chr9:5522509-5570021" ratio="3.06" status="known" type="amplification">
          <dna-evidence sample="SQ-US1564922.01-1" />
        </copy-number-alteration>
        <copy-number-alteration copy-number="9" equivocal="true" gene="CDKN2B" number-of-exons="5 of 5" position="chr9:22002170-22010784" ratio="2.08" status="unknown" type="amplification">
          <dna-evidence sample="SQ-US1564922.01-1" />
        </copy-number-alteration>
        <copy-number-alteration copy-number="9" equivocal="true" gene="MTAP" number-of-exons="8 of 8" position="chr9:21802699-21862058" ratio="2.02" status="unknown" type="amplification">
          <dna-evidence sample="SQ-US1564922.01-1" />
        </copy-number-alteration>
        <copy-number-alteration copy-number="10" equivocal="true" gene="PAX5" number-of-exons="10 of 10" position="chr9:36840530-37034069" ratio="2.05" status="unknown" type="amplification">
          <dna-evidence sample="SQ-US1564922.01-1" />
        </copy-number-alteration>
        <copy-number-alteration copy-number="10" equivocal="true" gene="TEK" number-of-exons="23 of 23" position="chr9:27109549-27229257" ratio="2.16" status="unknown" type="amplification">
          <dna-evidence sample="SQ-US1564922.01-1" />
        </copy-number-alteration>
        <copy-number-alteration copy-number="14" equivocal="false" gene="JAK2" number-of-exons="23 of 23" position="chr9:5021987-5126801" ratio="3.19" status="known" type="amplification">
          <dna-evidence sample="SQ-US1564922.01-1" />
        </copy-number-alteration>
        <copy-number-alteration copy-number="10" equivocal="true" gene="FANCG" number-of-exons="14 of 14" position="chr9:35074094-35079544" ratio="2.07" status="unknown" type="amplification">
          <dna-evidence sample="SQ-US1564922.01-1" />
        </copy-number-alteration>
      </copy-number-alterations>
      <rearrangements />
      <biomarkers>
        <microsatellite-instability status="MSS" />
        <tumor-mutation-burden score="0.0" status="low" unit="mutations-per-megabase" />
      </biomarkers>
      <non-human-content />
    </variant-report>
  </rr:ResultsPayload>
</rr:ResultsReport>
